|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
secoisolariciresinol results in increased activity of NR1I2 protein |
CTD |
PMID:15885729 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
increases expression |
EXP |
1-nitropropane results in increased expression of ABCB1B mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Acmsd |
aminocarboxymuconate semialdehyde decarboxylase |
increases expression |
EXP |
1-nitropropane results in increased expression of ACMSD mRNA |
CTD |
PMID:17070881 |
|
NCBI chr13:44,424,689...44,468,734
Ensembl chr13:44,424,689...44,468,734
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of ACSL3 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 9:84,569,601...84,593,565
Ensembl chr 9:84,569,597...84,593,565
|
|
G |
Aen |
apoptosis enhancing nuclease |
increases expression |
EXP |
1-nitropropane results in increased expression of AEN mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:140,584,328...140,593,749
Ensembl chr 1:140,584,380...140,593,745
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of AKR7A3 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 5:157,801,120...157,813,756
Ensembl chr 5:157,801,163...157,813,756
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression |
EXP |
1-nitropropane results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldh1a7 |
aldehyde dehydrogenase family 1, subfamily A7 |
increases expression |
EXP |
1-nitropropane results in increased expression of ALDH1A4 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:240,584,233...240,601,843
Ensembl chr 1:240,562,423...240,601,744
|
|
G |
Apoa2 |
apolipoprotein A2 |
increases expression |
EXP |
1-nitropropane results in increased expression of APOA2 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr13:89,596,872...89,598,805
Ensembl chr13:89,597,138...89,598,802
|
|
G |
Apoa4 |
apolipoprotein A4 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of APOA4 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 8:50,536,983...50,539,371
Ensembl chr 8:50,537,009...50,539,376
|
|
G |
Apoc3 |
apolipoprotein C3 |
increases expression |
EXP |
1-nitropropane results in increased expression of APOC3 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 8:50,529,318...50,531,498
Ensembl chr 8:50,529,318...50,531,498
|
|
G |
Atp6v1d |
ATPase H+ transporting V1 subunit D |
increases expression |
EXP |
1-nitropropane results in increased expression of ATP6V1D mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 6:102,032,271...102,047,754
Ensembl chr 6:102,032,276...102,047,758
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
1-nitropropane results in increased expression of BAX mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of BTG2 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
|
|
G |
C7 |
complement C7 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of C7 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 2:54,707,621...54,781,624
Ensembl chr 2:54,709,138...54,777,729
|
|
G |
Cblc |
Cbl proto-oncogene C |
decreases expression |
EXP |
1-nitropropane results in decreased expression of CBLC mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:80,699,321...80,716,146
Ensembl chr 1:80,699,323...80,716,146
|
|
G |
Ccng1 |
cyclin G1 |
increases expression |
EXP |
1-nitropropane results in increased expression of CCNG1 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr10:25,903,925...25,910,298
Ensembl chr10:25,903,911...25,910,325
|
|
G |
Cd276 |
Cd276 molecule |
decreases expression |
EXP |
1-nitropropane results in decreased expression of CD276 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 8:63,312,060...63,350,411
Ensembl chr 8:63,318,019...63,350,269
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression |
EXP |
1-nitropropane results in decreased expression of CDKN1A mRNA |
CTD |
PMID:17070881 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cpq |
carboxypeptidase Q |
decreases expression |
EXP |
1-nitropropane results in decreased expression of CPQ mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 7:71,709,174...72,167,413
Ensembl chr 7:71,709,157...72,167,417
|
|
G |
Cryab |
crystallin, alpha B |
decreases expression |
EXP |
1-nitropropane results in decreased expression of CRYAB mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 8:55,178,543...55,182,546
Ensembl chr 8:55,178,289...55,182,545
|
|
G |
Cyp2c13 |
cytochrome P450, family 2, subfamily c, polypeptide 13 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of CYP2C13 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:258,796,624...258,877,023
Ensembl chr 1:258,796,622...258,877,045
|
|
G |
Cyp4f5 |
cytochrome P450, family 4, subfamily f, polypeptide 5 |
increases expression |
EXP |
1-nitropropane results in increased expression of CYP4F5 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 7:14,559,806...14,574,345
Ensembl chr 7:14,529,482...14,574,361
|
|
G |
Ddah1 |
dimethylarginine dimethylaminohydrolase 1 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of DDAH1 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 2:251,634,368...251,766,009
Ensembl chr 2:251,634,431...251,766,014
|
|
G |
Epcam |
epithelial cell adhesion molecule |
decreases expression |
EXP |
1-nitropropane results in decreased expression of EPCAM mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 6:11,282,194...11,308,870
Ensembl chr 6:11,281,964...11,298,216
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of EPHX1 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
EXP |
1-nitropropane results in increased expression of FAS mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fhit |
fragile histidine triad diadenosine triphosphatase |
increases expression |
EXP |
1-nitropropane results in increased expression of FHIT mRNA |
CTD |
PMID:17070881 |
|
NCBI chr15:15,697,292...16,862,873
|
|
G |
Gria3 |
glutamate ionotropic receptor AMPA type subunit 3 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of GRIA3 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr X:127,561,843...127,829,763
Ensembl chr X:127,562,660...127,829,753
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of GSTM1 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Hsd17b6 |
hydroxysteroid (17-beta) dehydrogenase 6 |
increases expression |
EXP |
1-nitropropane results in increased expression of HSD17B6 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 7:2,412,370...2,431,249
Ensembl chr 7:2,412,363...2,431,197 Ensembl chr13:2,412,363...2,431,197
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
decreases expression |
EXP |
1-nitropropane results in decreased expression of IL2RA mRNA |
CTD |
PMID:17070881 |
|
NCBI chr17:70,500,672...70,547,929
Ensembl chr17:70,499,083...70,548,071
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
increases expression |
EXP |
1-nitropropane results in increased expression of MGMT mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression |
EXP |
1-nitropropane results in increased expression of NUPR1 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:194,767,484...194,769,519
Ensembl chr 1:194,767,474...194,769,524
|
|
G |
Olr37 |
olfactory receptor 37 |
increases expression |
EXP |
1-nitropropane results in increased expression of OLR37 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:164,755,094...164,756,059
|
|
G |
Phlda3 |
pleckstrin homology-like domain, family A, member 3 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of PHLDA3 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr13:52,588,917...52,592,002
Ensembl chr13:52,588,917...52,592,001
|
|
G |
Rhobtb2 |
Rho-related BTB domain containing 2 |
increases expression |
EXP |
1-nitropropane results in increased expression of RHOBTB2 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr15:51,465,148...51,485,562
Ensembl chr15:51,465,148...51,485,692
|
|
G |
Serpina7 |
serpin family A member 7 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of SERPINA7 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr X:110,226,565...110,232,202
Ensembl chr X:110,226,572...110,232,179
|
|
G |
Slc16a10 |
solute carrier family 16 member 10 |
increases expression |
EXP |
1-nitropropane results in increased expression of SLC16A10 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr20:45,138,433...45,260,155
Ensembl chr20:45,143,453...45,260,119
|
|
G |
Spink1 |
serine peptidase inhibitor, Kazal type 1 |
increases expression |
EXP |
1-nitropropane results in increased expression of SPINK1 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr18:38,221,919...38,242,092
Ensembl chr18:38,221,681...38,242,119
|
|
G |
Sugct |
succinylCoA:glutarate-CoA transferase |
decreases expression |
EXP |
1-nitropropane results in decreased expression of SUGCT mRNA |
CTD |
PMID:17070881 |
|
NCBI chr17:49,991,314...51,030,950
|
|
G |
Sulf2 |
sulfatase 2 |
increases expression |
EXP |
1-nitropropane results in increased expression of SULF2 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 3:162,791,349...162,872,984
Ensembl chr 3:162,791,355...162,872,831
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
increases expression |
EXP |
1-nitropropane results in increased expression of SULT2A1 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
|
|
G |
Zmat3 |
zinc finger, matrin type 3 |
decreases expression |
EXP |
1-nitropropane results in decreased expression of ZMAT3 mRNA |
CTD |
PMID:17070881 |
|
NCBI chr 2:118,715,229...118,746,109
Ensembl chr 2:118,721,334...118,745,766
|
|
|
G |
Capn1 |
calpain 1 |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [CAPN1 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 |
|
NCBI chr 1:221,346,081...221,370,965
Ensembl chr 1:221,346,066...221,370,322
|
|
G |
Capn7 |
calpain 7 |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [CAPN7 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 |
|
NCBI chr16:7,435,541...7,472,483
Ensembl chr16:7,435,634...7,471,807
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] inhibits the reaction [[vistusertib co-treated with Chloroquine] results in increased activity of CASP3 protein] |
CTD |
PMID:26853465 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSB protein; aloxistatin inhibits the reaction [CTSB protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 PMID:32186374 |
|
NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSD protein |
CTD |
PMID:32186374 |
|
NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [CTSL protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 |
|
NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
|
|
G |
Ddx3x |
DEAD-box helicase 3, X-linked |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of DDX3X protein] |
CTD |
PMID:30821613 |
|
NCBI chr X:10,400,363...10,414,010
Ensembl chr X:10,400,366...10,413,995
|
|
G |
Eif4a1 |
eukaryotic translation initiation factor 4A1 |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4A1 protein] |
CTD |
PMID:30821613 |
|
NCBI chr10:56,271,257...56,276,764
Ensembl chr10:56,271,257...56,276,764
|
|
G |
Eif4h |
eukaryotic translation initiation factor 4H |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4H protein] |
CTD |
PMID:30821613 |
|
NCBI chr12:25,093,119...25,109,805
Ensembl chr12:25,093,149...25,109,799
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] results in increased expression of LAMP2 protein |
CTD |
PMID:32186374 |
|
NCBI chr X:124,722,628...124,766,079
Ensembl chr X:124,722,628...124,766,044
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in decreased degradation of MAP1LC3B protein modified form |
CTD |
PMID:27635674 |
|
NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein [aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [Dronabinol co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [HU 211 co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein |
CTD |
PMID:32186374 PMID:32773031 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
decreases response to substance |
ISO |
ADRB2 protein results in decreased susceptibility to Busulfan |
CTD |
PMID:7202579 |
|
NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
|
|
G |
Anp32b |
acidic nuclear phosphoprotein 32 family member B |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of ANP32B protein |
CTD |
PMID:20933509 |
|
NCBI chr 5:62,070,709...62,094,633
Ensembl chr 5:62,071,346...62,094,633
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases response to substance |
ISO |
APEX1 protein mutant form results in increased susceptibility to Busulfan |
CTD |
PMID:19470598 |
|
NCBI chr15:27,849,943...27,852,083
Ensembl chr15:27,849,979...27,852,082
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Busulfan inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:18324785 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
multiple interactions affects response to substance |
ISO |
ARHGDIA mRNA affects the reaction [Busulfan results in increased activity of CASP3 protein] ARHGDIA mRNA affects the susceptibility to Busulfan |
CTD |
PMID:17264767 |
|
NCBI chr10:109,754,012...109,757,506
Ensembl chr10:109,754,004...109,757,550
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of ATM protein |
CTD |
PMID:20933509 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
decreases expression |
EXP |
Busulfan results in decreased expression of BMP4 mRNA |
CTD |
PMID:15786497 |
|
NCBI chr15:20,776,060...20,791,013
Ensembl chr15:20,776,054...20,822,740
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of CASP3 protein; [decitabine co-treated with Busulfan] results in increased activity of CASP3 protein; ARHGDIA mRNA affects the reaction [Busulfan results in increased activity of CASP3 protein] |
CTD |
PMID:17264767 PMID:18339423 PMID:19732952 PMID:20933509 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions |
ISO |
Busulfan results in increased activity of CASP8 protein [decitabine co-treated with Busulfan] results in increased activity of CASP8 protein; pifithrin inhibits the reaction [[decitabine co-treated with Busulfan] results in increased activity of CASP8 protein] |
CTD |
PMID:18339423 PMID:19732952 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of CASP9 protein; pifithrin inhibits the reaction [[decitabine co-treated with Busulfan] results in increased activity of CASP9 protein] |
CTD |
PMID:19732952 PMID:20933509 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cdc25b |
cell division cycle 25B |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of CDC25B protein |
CTD |
PMID:20933509 |
|
NCBI chr 3:123,731,539...123,741,696
Ensembl chr 3:123,731,539...123,741,339
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Busulfan results in decreased expression of CDK2 mRNA |
CTD |
PMID:15388331 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Busulfan results in decreased expression of CDK4 mRNA |
CTD |
PMID:15388331 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
Busulfan results in increased expression of CDKN1A protein [clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased expression of CDKN1A protein |
CTD |
PMID:16882877 PMID:20933509 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression |
ISO |
Busulfan results in increased expression of CDKN2A mRNA |
CTD |
PMID:14500376 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of CHEK1 protein |
CTD |
PMID:20933509 |
|
NCBI chr 8:39,181,162...39,201,588
Ensembl chr 8:39,181,163...39,243,882
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of CHEK2 protein |
CTD |
PMID:20933509 |
|
NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
affects expression |
ISO |
Busulfan affects the expression of COL4A1 mRNA |
CTD |
PMID:15941629 |
|
NCBI chr16:83,522,162...83,632,153
Ensembl chr16:83,522,162...83,632,153
|
|
G |
Faslg |
Fas ligand |
decreases expression |
ISO |
Busulfan results in decreased expression of FASL mRNA |
CTD |
PMID:15388331 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
decreases expression |
EXP |
Busulfan results in decreased expression of FGF8 mRNA |
CTD |
PMID:15786497 |
|
NCBI chr 1:265,492,949...265,498,965
Ensembl chr 1:265,493,124...265,498,831
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
affects expression increases expression |
ISO |
Busulfan affects the expression of GDNF mRNA Busulfan results in increased expression of GDNF mRNA |
CTD |
PMID:20684317 PMID:22082982 PMID:26524245 |
|
NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions decreases expression |
ISO |
Busulfan results in decreased expression of and results in decreased activity of GPX4 protein; Deferoxamine inhibits the reaction [Busulfan results in decreased expression of GPX4 protein]; ferrostatin-1 inhibits the reaction [Busulfan results in decreased expression of and results in decreased activity of GPX4 protein]; sulforafan inhibits the reaction [Busulfan results in decreased expression of and results in decreased activity of GPX4 protein] |
CTD |
PMID:32416107 |
|
NCBI chr 7:12,516,357...12,519,154
Ensembl chr 7:12,516,352...12,519,154
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions affects response to substance affects metabolic processing affects abundance decreases response to substance |
ISO |
GSTA1 protein affects the metabolism of [Busulfan co-treated with Glutathione] GSTA1 polymorphism affects the susceptibility to Busulfan GSTA1 gene polymorphism affects the metabolism of Busulfan; GSTA1 protein affects the metabolism of Busulfan GSTA1 gene polymorphism affects the abundance of Busulfan GSTA1 protein results in decreased susceptibility to Busulfan |
CTD |
PMID:8886613 PMID:10437668 PMID:10570028 PMID:12429583 PMID:20672371 PMID:21135089 PMID:21215809 PMID:21441958 |
|
NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
affects metabolic processing affects abundance affects response to substance multiple interactions |
ISO |
GSTM1 protein affects the metabolism of Busulfan GSTM1 gene polymorphism affects the abundance of Busulfan GSTM1 gene polymorphism affects the susceptibility to Busulfan [GSTM1 gene polymorphism co-treated with GSTT1 gene polymorphism] affects the metabolism of Busulfan; [GSTM1 protein co-treated with CYP2C9 protein] results in increased susceptibility to [Busulfan co-treated with Cyclophosphamide] |
CTD |
PMID:8886613 PMID:15142875 PMID:19584821 PMID:20672371 PMID:21215809 PMID:28744217 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
affects metabolic processing affects abundance |
ISO |
GSTP1 protein affects the metabolism of Busulfan GSTP1 gene polymorphism affects the abundance of Busulfan |
CTD |
PMID:8886613 PMID:20672371 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
multiple interactions |
ISO |
[GSTM1 gene polymorphism co-treated with GSTT1 gene polymorphism] affects the metabolism of Busulfan |
CTD |
PMID:21215809 |
|
NCBI chr20:13,799,102...13,816,527
Ensembl chr20:13,799,102...13,816,526
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation multiple interactions |
ISO |
Busulfan results in increased phosphorylation of H2AX protein [Clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased expression of H2AX protein |
CTD |
PMID:18339423 PMID:20933509 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Inhba |
inhibin subunit beta A |
multiple interactions increases expression |
ISO |
bisindolylmaleimide I inhibits the reaction [Busulfan results in increased expression of INHBA mRNA]; bisindolylmaleimide I inhibits the reaction [Busulfan results in increased expression of INHBA protein] Busulfan results in increased expression of INHBA mRNA; Busulfan results in increased expression of INHBA protein |
CTD |
PMID:12966370 PMID:22286157 |
|
NCBI chr17:51,894,869...51,919,998
Ensembl chr17:51,898,217...51,912,496
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression |
ISO |
Busulfan results in decreased expression of KIT mRNA |
CTD |
PMID:15388331 |
|
NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
|
|
G |
Lama1 |
laminin subunit alpha 1 |
affects expression |
ISO |
Busulfan affects the expression of LAMA1 mRNA |
CTD |
PMID:15941629 |
|
NCBI chr 9:115,916,907...116,042,123
Ensembl chr 9:115,916,907...116,042,123
|
|
G |
Lama4 |
laminin subunit alpha 4 |
affects expression |
ISO |
Busulfan affects the expression of LAMA4 mRNA |
CTD |
PMID:15941629 |
|
NCBI chr20:44,060,715...44,201,966
Ensembl chr20:44,060,731...44,209,614
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases activity |
ISO |
Busulfan results in increased activity of MAPK1 protein |
CTD |
PMID:16882877 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases activity |
ISO |
Busulfan results in increased activity of MAPK3 protein |
CTD |
PMID:16882877 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mgst2 |
microsomal glutathione S-transferase 2 |
decreases response to substance |
ISO |
MGST2 protein results in decreased susceptibility to Busulfan |
CTD |
PMID:15779864 |
|
NCBI chr 2:140,708,396...140,727,381
Ensembl chr 2:140,708,397...140,727,281
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in decreased expression of MYC protein |
CTD |
PMID:20933509 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Nanos2 |
nanos C2HC-type zinc finger 2 |
decreases expression |
ISO |
Busulfan results in decreased expression of NANOS2 mRNA; Busulfan results in decreased expression of NANOS2 protein |
CTD |
PMID:26524245 |
|
NCBI chr 1:79,894,450...79,895,910
Ensembl chr 1:79,894,450...79,895,910
|
|
G |
Nanos3 |
nanos C2HC-type zinc finger 3 |
decreases expression |
ISO |
Busulfan results in decreased expression of NANOS3 mRNA |
CTD |
PMID:26524245 |
|
NCBI chr19:25,284,907...25,288,680
Ensembl chr19:25,284,909...25,288,335
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
decreases expression multiple interactions |
ISO |
Busulfan results in decreased expression of NFE2L2 protein Deferoxamine inhibits the reaction [Busulfan results in decreased expression of NFE2L2 protein]; ferrostatin-1 inhibits the reaction [Busulfan results in decreased expression of NFE2L2 protein]; sulforafan inhibits the reaction [Busulfan results in decreased expression of NFE2L2 protein] |
CTD |
PMID:32416107 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Npm1 |
nucleophosmin 1 |
multiple interactions |
ISO |
NPM1 gene mutant form results in increased susceptibility to [Busulfan co-treated with Idarubicin] |
CTD |
PMID:20172040 |
|
NCBI chr10:18,080,949...18,091,062
Ensembl chr10:18,080,950...18,090,950
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of PARP1 protein; [decitabine co-treated with Busulfan] results in increased cleavage of PARP1 protein; pifithrin inhibits the reaction [[decitabine co-treated with Busulfan] results in increased cleavage of PARP1 protein] Busulfan results in increased cleavage of PARP1 protein |
CTD |
PMID:18339423 PMID:19732952 PMID:20933509 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Phb |
prohibitin |
affects expression |
ISO |
Busulfan affects the expression of PHB mRNA |
CTD |
PMID:15388331 |
|
NCBI chr10:83,476,107...83,488,878
Ensembl chr10:83,476,107...83,488,878
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
Busulfan results in increased expression of PTGS2 mRNA ferrostatin-1 inhibits the reaction [Busulfan results in increased expression of PTGS2 mRNA] |
CTD |
PMID:12966370 PMID:32416107 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rad51 |
RAD51 recombinase |
decreases expression |
ISO |
Busulfan results in decreased expression of RAD51 mRNA |
CTD |
PMID:15388331 |
|
NCBI chr 3:110,918,240...110,942,920
Ensembl chr 3:110,918,243...110,942,917
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
ISO |
Busulfan results in decreased phosphorylation of RB1 protein |
CTD |
PMID:15388331 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Sat2 |
spermidine/spermine N1-acetyltransferase family member 2 |
increases expression |
ISO |
Busulfan results in increased expression of SAT2 mRNA; Busulfan results in increased expression of SAT2 protein |
CTD |
PMID:28578006 |
|
NCBI chr10:56,227,703...56,229,796
Ensembl chr10:56,227,692...56,229,850
|
|
G |
Serpinc1 |
serpin family C member 1 |
affects expression |
ISO |
Busulfan affects the expression of SERPINC1 protein |
CTD |
PMID:15580502 |
|
NCBI chr13:78,806,107...78,820,375
Ensembl chr13:78,805,347...78,833,192
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression multiple interactions |
ISO |
Busulfan results in increased expression of SERPINE1 mRNA; Busulfan results in increased expression of SERPINE1 protein 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Busulfan results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:22286157 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
decreases expression multiple interactions |
ISO |
Busulfan results in decreased expression of SLC40A1 protein Deferoxamine inhibits the reaction [Busulfan results in decreased expression of SLC40A1 protein]; ferrostatin-1 inhibits the reaction [Busulfan results in decreased expression of SLC40A1 protein]; sulforafan inhibits the reaction [Busulfan results in decreased expression of SLC40A1 protein] |
CTD |
PMID:32416107 |
|
NCBI chr 9:52,819,451...52,830,461
Ensembl chr 9:52,894,365...52,912,293
|
|
G |
Smc1a |
structural maintenance of chromosomes 1A |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of SMC1A protein |
CTD |
PMID:20933509 |
|
NCBI chr X:21,710,976...21,755,708
Ensembl chr X:21,711,019...21,755,525
|
|
G |
Smc3 |
structural maintenance of chromosomes 3 |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased phosphorylation of SMC3 protein |
CTD |
PMID:20933509 |
|
NCBI chr 1:274,310,120...274,352,856
Ensembl chr 1:274,309,758...274,352,854
|
|
G |
Stra8 |
stimulated by retinoic acid 8 |
decreases expression |
ISO |
Busulfan results in decreased expression of STRA8 mRNA |
CTD |
PMID:15388331 |
|
NCBI chr 4:62,447,724...62,474,802
Ensembl chr 4:62,457,694...62,473,360
|
|
G |
Tf |
transferrin |
multiple interactions increases expression |
ISO |
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [Busulfan results in increased expression of TF mRNA] Busulfan results in increased expression of TF mRNA; Busulfan results in increased expression of TF protein |
CTD |
PMID:12966370 PMID:22286157 |
|
NCBI chr 8:111,694,570...111,721,275
Ensembl chr 8:111,673,547...111,721,333
|
|
G |
Tfpi |
tissue factor pathway inhibitor |
decreases expression |
ISO |
Busulfan results in decreased expression of TFPI mRNA |
CTD |
PMID:22286157 |
|
NCBI chr 3:71,852,738...71,902,127
Ensembl chr 3:71,852,744...71,893,618
|
|
G |
Tfrc |
transferrin receptor |
decreases expression multiple interactions |
ISO |
Busulfan results in decreased expression of TFRC protein Deferoxamine promotes the reaction [Busulfan results in decreased expression of TFRC protein] |
CTD |
PMID:32416107 |
|
NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
Busulfan results in increased expression of TGFB1 mRNA |
CTD |
PMID:22286157 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Thbs1 |
thrombospondin 1 |
increases expression |
ISO |
Busulfan results in increased expression of THBS1 mRNA |
CTD |
PMID:22286157 |
|
NCBI chr 3:109,862,120...109,873,466
Ensembl chr 3:109,862,117...109,873,466
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
Busulfan results in increased expression of TNF mRNA |
CTD |
PMID:22286157 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
Busulfan affects the phosphorylation of and affects the activity of TP53 protein |
CTD |
PMID:16882877 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
decreases activity |
EXP |
Busulfan results in decreased activity of TXNRD1 protein |
CTD |
PMID:16085187 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
[clofarabine co-treated with fludarabine co-treated with Busulfan] results in decreased expression of XIAP protein |
CTD |
PMID:20933509 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|
G |
Zbtb16 |
zinc finger and BTB domain containing 16 |
increases expression |
ISO |
Busulfan results in increased expression of ZBTB16 mRNA |
CTD |
PMID:26524245 |
|
NCBI chr 8:52,980,226...53,146,765
Ensembl chr 8:52,985,313...53,146,953
|
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
ISO |
2-butanol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr15:42,808,897...42,825,179
Ensembl chr15:42,808,897...42,825,179
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
ISO |
2-butanol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr 8:59,610,489...59,629,073
Ensembl chr 8:59,609,693...59,629,133
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
EXP |
2-butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:14769825 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Gh1 |
growth hormone 1 |
affects folding |
ISO |
2-butanol affects the folding of GH1 protein |
CTD |
PMID:11064379 |
|
NCBI chr10:94,486,204...94,488,181
Ensembl chr10:94,486,205...94,488,180
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
butane results in increased expression of BAX mRNA |
CTD |
PMID:33064461 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO |
butane results in decreased expression of FN1 mRNA |
CTD |
PMID:33064461 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases activity increases expression |
EXP |
1,3-butylene glycol results in increased activity of CYP2E1 protein 1,3-butylene glycol results in increased expression of CYP2E1 protein |
CTD |
PMID:2919394 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
multiple interactions |
ISO |
[AKR1B1 protein results in increased reduction of Acetoin] which results in increased chemical synthesis of 2,3-butylene glycol |
CTD |
PMID:23295224 |
|
NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
multiple interactions |
ISO |
[AKR1B10 protein results in increased reduction of Acetoin] which results in increased chemical synthesis of 2,3-butylene glycol |
CTD |
PMID:23295224 |
|
NCBI chr 4:61,813,265...61,830,371
Ensembl chr 4:61,771,970...61,828,657
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
increases metabolic processing |
ISO |
ALDH2 protein results in increased metabolism of 2,3-butylene glycol |
CTD |
PMID:10064379 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased expression of BDNF protein; ifenprodil inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased expression of BDNF protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased expression of BDNF protein] |
CTD |
PMID:24718106 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions increases secretion |
EXP |
Carbon Dioxide inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]; Carbon Dioxide inhibits the reaction [Potassium Chloride results in increased secretion of CALCA protein]; Carbon Dioxide inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in increased secretion of CALCA protein] Carbon Dioxide results in increased secretion of CALCA protein |
CTD |
PMID:18052948 |
|
NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of CAMK2B protein; ifenprodil inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of CAMK2B protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of CAMK2B protein] |
CTD |
PMID:24718106 |
|
NCBI chr14:86,208,876...86,297,727
Ensembl chr14:86,208,901...86,297,652
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of CREB1 protein; ifenprodil inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of CREB1 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:24718106 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crh |
corticotropin releasing hormone |
increases response to substance |
ISO |
CRH protein results in increased susceptibility to Carbon Dioxide |
CTD |
PMID:8957205 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Dlg3 |
discs large MAGUK scaffold protein 3 |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of DLG3 protein; ifenprodil inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of DLG3 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of DLG3 protein] |
CTD |
PMID:24718106 |
|
NCBI chr X:70,596,246...70,648,529
Ensembl chr X:70,596,576...70,648,532
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of GRIN2B protein; ifenprodil inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of GRIN2B protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of GRIN2B protein] |
CTD |
PMID:24718106 |
|
NCBI chr 4:169,541,620...170,000,216
Ensembl chr 4:169,560,387...169,999,873
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK1 protein; [Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK1 mRNA; [Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK1 protein; ifenprodil inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK1 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK1 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24718106 PMID:25004876 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK3 protein; [Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK3 mRNA; [Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK3 protein; ifenprodil inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK3 protein]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of MAPK3 mRNA]; notoginsenoside R1 inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:24718106 PMID:25004876 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Neil1 |
nei-like DNA glycosylase 1 |
affects abundance |
ISO |
NEIL1 affects the abundance of Carbon Dioxide |
CTD |
PMID:21285402 |
|
NCBI chr 8:61,817,258...61,824,023
Ensembl chr 8:61,817,258...61,823,102
|
|
G |
Ngb |
neuroglobin |
affects binding |
ISO |
Carbon Dioxide binds to [Heme binds to NGB protein] |
CTD |
PMID:16684569 |
|
NCBI chr 6:111,126,259...111,131,699
Ensembl chr 6:111,126,261...111,132,320
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
PPARA protein promotes the reaction [[GW 7647 results in increased oxidation of Palmitic Acid] which results in increased abundance of Carbon Dioxide] |
CTD |
PMID:21324916 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Rapgef3 |
Rap guanine nucleotide exchange factor 3 |
multiple interactions |
ISO |
[RAPGEF3 protein affects the susceptibility to Dietary Fats] which affects the chemical synthesis of Carbon Dioxide |
CTD |
PMID:27381457 |
|
NCBI chr 7:139,232,263...139,254,668
Ensembl chr 7:139,232,251...139,254,551
|
|
G |
Slc9a1 |
solute carrier family 9 member A1 |
affects response to substance |
EXP |
SLC9A1 protein affects the susceptibility to Carbon Dioxide |
CTD |
PMID:16831598 |
|
NCBI chr 5:151,573,122...151,626,360
Ensembl chr 5:151,573,092...151,627,316
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[[[Bicarbonates co-treated with Carbon Dioxide] promotes the reaction [SOD1 protein binds to peroxycarbonic acid]] which results in increased reduction of peroxycarbonic acid] which results in increased chemical synthesis of Carbonates; [[Bicarbonates co-treated with Carbon Dioxide] promotes the reaction [SOD1 protein binds to peroxycarbonic acid]] which results in increased reduction of peroxycarbonic acid; [[SOD1 protein results in increased metabolism of Hydrogen Peroxide] results in increased oxidation of [Bicarbonates co-treated with Carbon Dioxide]] which results in increased chemical synthesis of Carbonates; [Bicarbonates co-treated with Carbon Dioxide] promotes the reaction [SOD1 protein binds to peroxycarbonic acid]; [Bicarbonates co-treated with Carbon Dioxide] promotes the reaction [SOD1 protein results in increased metabolism of Hydrogen Peroxide]; [SOD1 protein results in increased metabolism of Hydrogen Peroxide] results in increased oxidation of [Bicarbonates co-treated with Carbon Dioxide] |
CTD |
PMID:19243126 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Syngap1 |
synaptic Ras GTPase activating protein 1 |
multiple interactions |
EXP |
[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of SYNGAP1 protein; ifenprodil inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of SYNGAP1 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of SYNGAP1 protein] |
CTD |
PMID:24718106 |
|
NCBI chr20:5,535,434...5,564,657
Ensembl chr20:5,535,432...5,564,437
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
increases expression |
EXP |
Carbon Dioxide results in increased expression of TPI1 mRNA |
CTD |
PMID:14762718 |
|
NCBI chr 4:157,328,375...157,331,905
Ensembl chr 4:157,328,379...157,331,905
|
|
G |
Trh |
thyrotropin releasing hormone |
increases response to substance |
ISO |
TRH protein results in increased susceptibility to Carbon Dioxide |
CTD |
PMID:8957205 |
|
NCBI chr 4:124,110,716...124,113,242
Ensembl chr 4:124,110,716...124,113,242
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
increases activity |
EXP |
Carbon Dioxide results in increased activity of TRPA1 protein |
CTD |
PMID:20881114 |
|
NCBI chr 5:3,783,247...3,836,485
Ensembl chr 5:3,783,247...3,836,485
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
affects response to substance |
EXP |
TRPV1 protein affects the susceptibility to Carbon Dioxide |
CTD |
PMID:16831598 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one promotes the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]] |
CTD |
PMID:31348943 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one promotes the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of AKT1 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:31348943 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Tunicamycin results in increased secretion of APP protein modified form] |
CTD |
PMID:22115781 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of BAX protein |
CTD |
PMID:21209419 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of BCL2 protein |
CTD |
PMID:21209419 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT10 mRNA] |
CTD |
PMID:23566955 |
|
NCBI chr17:26,955,142...27,112,820
Ensembl chr17:26,955,142...27,112,820
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of and results in increased activity of CASP3 protein |
CTD |
PMID:21209419 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of CCND1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of CCND1 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester co-treated with 1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one] inhibits the reaction [polyhexamethyleneguanidine results in decreased expression of CDH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased secretion of CDH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium results in increased cleavage of CDH1 protein] |
CTD |
PMID:18791180 PMID:31348943 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased cleavage of CDH2 protein] |
CTD |
PMID:23876460 |
|
NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of CSF1 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of ENO2 mRNA] |
CTD |
PMID:24929042 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of FLT1 protein] |
CTD |
PMID:21843347 |
|
NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Hydrogen Peroxide results in increased expression of FOXO3 protein] |
CTD |
PMID:25108166 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
multiple interactions decreases expression |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Hydrogen Peroxide results in increased expression of HES1 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of HES1 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of HES1 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of HES1 protein |
CTD |
PMID:19160421 PMID:24223152 PMID:25005833 PMID:25108166 PMID:32041402 |
|
NCBI chr11:74,312,837...74,315,249
Ensembl chr11:74,312,806...74,315,248
|
|
G |
Hey1 |
hes-related family bHLH transcription factor with YRPW motif 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HEY1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY1 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr 2:95,320,147...95,322,701
Ensembl chr 2:95,320,283...95,322,696
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HEY2 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY2 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Niclosamide results in increased expression of HEY2 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of HEY2 mRNA] |
CTD |
PMID:19160421 PMID:32041402 |
|
NCBI chr 1:29,191,170...29,201,257
Ensembl chr 1:29,191,192...29,201,531
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Hydrogen Peroxide results in increased expression of HIF1A protein] |
CTD |
PMID:25108166 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of HMGB1 protein] |
CTD |
PMID:21843347 |
|
NCBI chr12:7,082,529...7,090,246
Ensembl chr16:37,500,017...37,502,237
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL10 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL1B protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL1B mRNA] |
CTD |
PMID:21843347 PMID:24223152 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL6 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein] |
CTD |
PMID:21843347 PMID:24223152 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased expression of ITGAM protein] |
CTD |
PMID:28130038 |
|
NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
|
|
G |
Ivl |
involucrin |
decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of IVL mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of IVL protein |
CTD |
PMID:18633435 |
|
NCBI chr 2:192,761,171...192,773,346
Ensembl chr 2:192,761,538...192,763,577
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of JAG1 mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of JAG1 protein |
CTD |
PMID:18633435 |
|
NCBI chr 3:130,079,361...130,114,781
Ensembl chr 3:130,079,361...130,114,770
|
|
G |
Krt1 |
keratin 1 |
multiple interactions decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [U 0126 results in increased expression of KRT1 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT1 mRNA |
CTD |
PMID:18633435 PMID:23566955 |
|
NCBI chr 7:143,448,318...143,453,544
Ensembl chr 7:143,448,318...143,453,544
|
|
G |
Krt10 |
keratin 10 |
multiple interactions decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT10 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [U 0126 results in increased expression of KRT10 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT10 mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT10 protein |
CTD |
PMID:18633435 PMID:23566955 |
|
NCBI chr10:87,296,445...87,301,307
Ensembl chr10:87,296,451...87,300,736
|
|
G |
Lgr5 |
leucine rich repeat containing G protein coupled receptor 5 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of LGR5 mRNA] |
CTD |
PMID:32041402 |
|
NCBI chr 7:58,447,097...58,587,787
Ensembl chr 7:58,448,277...58,587,787
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of MAP2 mRNA] |
CTD |
PMID:24929042 |
|
NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions increases expression |
ISO |
Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of MDM2 protein] |
CTD |
PMID:25005833 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of MYD88 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of MYD88 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of NOS2 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of NOS2 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Notch1 |
notch receptor 1 |
multiple interactions decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased expression of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Hydrogen Peroxide results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [phenethyl isothiocyanate results in increased cleavage of and results in increased activity of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [polyhexamethyleneguanidine results in increased cleavage of NOTCH1 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased cleavage of and results in decreased activity of NOTCH1 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency affects the localization of NOTCH1 protein modified form]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Tunicamycin results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Oxygen deficiency results in increased expression of NOTCH1 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH1 protein modified form |
CTD |
PMID:18633435 PMID:22039516 PMID:22115781 PMID:24223152 PMID:25108166 PMID:25118938 PMID:28130038 PMID:31348943 |
|
NCBI chr 3:3,905,562...3,951,015
Ensembl chr 3:3,905,453...3,951,025
|
|
G |
Notch2 |
notch receptor 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased cleavage of and results in decreased activity of NOTCH2 protein |
CTD |
PMID:22039516 |
|
NCBI chr 2:200,187,184...200,320,403
Ensembl chr 2:200,187,179...200,320,215
|
|
G |
Numb |
NUMB, endocytic adaptor protein |
increases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of NUMB protein |
CTD |
PMID:25005833 |
|
NCBI chr 6:107,279,917...107,325,345
Ensembl chr 6:107,279,920...107,325,345
|
|
G |
Pml |
PML nuclear body scaffold |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased degradation of [PML protein mutant form binds to RARA protein mutant form]] |
CTD |
PMID:28130038 |
|
NCBI chr 8:63,002,515...63,034,310
Ensembl chr 8:63,004,870...63,034,226
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium results in increased expression of PTGS2 mRNA] |
CTD |
PMID:18791180 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rara |
retinoic acid receptor, alpha |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased degradation of [PML protein mutant form binds to RARA protein mutant form]] |
CTD |
PMID:28130038 |
|
NCBI chr10:86,838,819...86,884,224
Ensembl chr10:86,860,685...86,884,210
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
multiple interactions increases expression |
EXP ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of RBPJ mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of RBPJ protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cycloheximide results in decreased expression of RBPJ protein] |
CTD |
PMID:22302987 PMID:24223152 |
|
NCBI chr14:59,657,738...59,865,427
Ensembl chr14:59,658,935...59,735,450
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency affects the localization of RELA protein modified form]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of RELA protein] |
CTD |
PMID:24223152 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TGFB1 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TLR4 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TNF protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TNF mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein] |
CTD |
PMID:25005833 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TRAF6 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TRAF6 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 3:91,252,829...91,271,607
Ensembl chr 3:91,252,829...91,271,607
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of TUBB3 mRNA] |
CTD |
PMID:24929042 |
|
NCBI chr19:56,220,759...56,229,813
Ensembl chr19:56,220,755...56,229,813
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein] |
CTD |
PMID:21843347 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vil1 |
villin 1 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of VIL1 mRNA] |
CTD |
PMID:32041402 |
|
NCBI chr 9:81,689,802...81,717,623
Ensembl chr 9:81,689,802...81,717,621
|
|
|
G |
A4galt |
alpha 1,4-galactosyltransferase (P blood group) |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of A4GALT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:124,085,832...124,110,440
Ensembl chr 7:124,085,834...124,089,385
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ABCG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Ak5 |
adenylate kinase 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of AK5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:257,671,772...257,864,385
Ensembl chr 2:257,671,772...257,864,385
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:30768133 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ALDOC mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:65,586,504...65,590,093
Ensembl chr10:65,586,504...65,590,126
|
|
G |
Amhr2 |
anti-Mullerian hormone receptor type 2 |
increases expression |
EXP |
diisobutyl phthalate results in increased expression of AMHR2 mRNA |
CTD |
PMID:22112501 |
|
NCBI chr 7:144,052,202...144,060,678
Ensembl chr 7:144,052,061...144,060,685
|
|
G |
Ar |
androgen receptor |
affects binding multiple interactions |
EXP ISO |
diisobutyl phthalate binds to AR protein diisobutyl phthalate inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; diisobutyl phthalate inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein] |
CTD |
PMID:14565775 PMID:15840436 PMID:28571686 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ARNT2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:146,399,217...146,556,437
Ensembl chr 1:146,399,217...146,556,171
|
|
G |
Astn1 |
astrotactin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:76,054,965...76,370,674
Ensembl chr13:76,055,410...76,370,674
|
|
G |
Astn2 |
astrotactin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:81,179,614...82,168,528
Ensembl chr 5:81,179,605...82,168,427
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:81,852,423...81,881,565
Ensembl chr 1:81,852,429...81,881,549
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BAX mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BCAT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:179,259,305...179,340,021
Ensembl chr 4:179,259,308...179,339,795
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of BCL2 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bend6 |
BEN domain containing 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BEND6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:38,297,253...38,351,312
Ensembl chr 9:38,297,322...38,351,024
|
|
G |
Bpgm |
bisphosphoglycerate mutase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BPGM mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:61,912,210...61,940,697
Ensembl chr 4:61,912,210...61,940,696
|
|
G |
Cacng7 |
calcium voltage-gated channel auxiliary subunit gamma 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CACNG7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:64,374,547...64,405,380
Ensembl chr 1:64,374,603...64,405,149
|
|
G |
Cadm3 |
cell adhesion molecule 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADM3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:91,842,311...91,873,126
Ensembl chr13:91,842,333...91,873,096
|
|
G |
Cadps |
calcium dependent secretion activator |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADPS mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:15,275,489...15,690,575
Ensembl chr15:15,275,541...15,667,778
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAMK4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:25,746,878...25,975,962
Ensembl chr18:25,749,098...25,965,957
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CASP8 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAT mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CCND2 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CDKN2A mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Celsr3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CELSR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:117,620,293...117,648,034
Ensembl chr 8:117,620,317...117,648,028
|
|
G |
Chga |
chromogranin A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGA mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:126,434,226...126,445,569
Ensembl chr 6:126,434,226...126,445,568
|
|
G |
Chgb |
chromogranin B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGB mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:125,428,050...125,441,601
Ensembl chr 3:125,428,260...125,441,594
|
|
G |
Cited1 |
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CITED1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:72,128,996...72,133,692
Ensembl chr X:72,128,994...72,133,692
|
|
G |
Clstn3 |
calsyntenin 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CLSTN3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:157,044,736...157,078,013
Ensembl chr 4:157,043,925...157,078,130
|
|
G |
Cntnap1 |
contactin associated protein 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CNTNAP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:89,087,904...89,103,615
Ensembl chr10:89,089,646...89,103,614
|
|
G |
Crmp1 |
collapsin response mediator protein 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CRMP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:78,266,931...78,312,777
Ensembl chr14:78,266,931...78,308,933
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in decreased expression of CYP11A1 mRNA; diisobutyl phthalate results in decreased expression of CYP11A1 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:16458459 PMID:21633115 PMID:22112501 PMID:28013214 PMID:30802670 |
|
NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of CYP11B1 mRNA |
CTD |
PMID:22112501 |
|
NCBI chr 7:116,248,759...116,255,205
Ensembl chr 7:116,156,219...116,255,167
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in decreased expression of CYP17A1 mRNA [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:22112501 PMID:28655647 PMID:30802670 |
|
NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
|
|
G |
Dclk3 |
doublecortin-like kinase 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DCLK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:119,691,567...119,744,484
Ensembl chr 8:119,691,388...119,744,506
|
|
G |
Ddc |
dopa decarboxylase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DDC mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:91,905,919...91,996,816
Ensembl chr14:91,905,919...91,996,774
|
|
G |
Dock3 |
dedicator of cyto-kinesis 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DOCK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:115,627,282...115,982,260
Ensembl chr 8:115,629,583...115,981,910
|
|
G |
Dpf1 |
double PHD fingers 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DPF1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:87,248,448...87,258,070
Ensembl chr 1:87,248,489...87,258,070
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:30,807,755...31,121,097
Ensembl chr 4:30,807,879...31,121,090
|
|
G |
Ece2 |
endothelin-converting enzyme 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ECE2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:83,948,896...83,985,429
Ensembl chr11:83,948,230...83,964,055
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EDN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Elmod1 |
ELMO domain containing 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ELMOD1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:58,486,078...58,542,884
Ensembl chr 8:58,486,078...58,542,844
|
|
G |
Emx2 |
empty spiracles homeobox 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EMX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:280,633,938...280,640,946
Ensembl chr 1:280,633,938...280,640,946
|
|
G |
Epdr1 |
ependymin related 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EPDR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:47,397,558...47,422,183
Ensembl chr17:47,397,558...47,422,182
|
|
G |
Espn |
espin |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESPN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:169,293,356...169,331,338
Ensembl chr 5:169,293,904...169,331,163
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases activity |
ISO |
diisobutyl phthalate binds to and results in increased activity of ESR1 protein; diisobutyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; Tamoxifen inhibits the reaction [diisobutyl phthalate binds to and results in increased activity of ESR1 protein] diisobutyl phthalate results in increased activity of ESR1 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESR1 mRNA |
CTD |
PMID:15840436 PMID:27633901 PMID:28013214 PMID:28571686 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases activity |
ISO |
diisobutyl phthalate binds to and results in increased activity of ESR2 protein; diisobutyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR2 protein] diisobutyl phthalate results in increased activity of ESR2 protein |
CTD |
PMID:27633901 PMID:28571686 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FABP5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:93,981,662...93,985,322
Ensembl chr 2:93,981,656...93,985,378
|
|
G |
Fam163a |
family with sequence similarity 163, member A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FAM163A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:73,741,674...73,820,114
Ensembl chr13:73,741,679...73,819,896
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FEZ1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:39,305,128...39,350,270
Ensembl chr 8:39,305,128...39,350,270
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FKBP1B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:29,975,863...29,987,252
Ensembl chr 6:29,977,797...29,987,451
|
|
G |
Flg |
filaggrin |
multiple interactions |
ISO |
[FLG gene polymorphism affects the susceptibility to diisobutyl phthalate] which affects the abundance of mono-isobutyl phthalate |
CTD |
PMID:24380925 |
|
NCBI chr 2:193,565,401...193,574,297
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FSHR mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 6:12,796,383...12,997,817
Ensembl chr 6:12,796,383...12,997,817
|
|
G |
Fxyd7 |
FXYD domain-containing ion transport regulator 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FXYD7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:89,474,601...89,484,069
Ensembl chr 1:89,474,601...89,483,988
|
|
G |
Gfra3 |
GDNF family receptor alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:27,491,860...27,520,133
Ensembl chr18:27,491,845...27,520,295
|
|
G |
Gfra4 |
GDNF family receptor alpha 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:123,573,394...123,582,431
Ensembl chr 3:123,578,997...123,581,518
|
|
G |
Ggta1 |
glycoprotein alpha-galactosyltransferase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GGTA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:14,614,099...14,701,185
Ensembl chr 3:14,614,122...14,644,951
|
|
G |
Gng2 |
G protein subunit gamma 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GNG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:4,748,242...4,853,555
Ensembl chr15:4,850,122...4,853,555
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GPX1 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSR mRNA |
CTD |
PMID:28013214 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSTA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:27,357,490...27,417,023
Ensembl chr 9:27,402,381...27,417,023
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of HMGCR mRNA |
CTD |
PMID:28655647 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of HMGCS1 mRNA |
CTD |
PMID:28655647 |
|
NCBI chr 2:52,427,351...52,445,082
Ensembl chr 2:52,431,601...52,445,055
|
|
G |
Hoxb8 |
homeo box B8 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXB8 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:84,131,484...84,133,874
Ensembl chr10:84,131,495...84,133,246
|
|
G |
Hoxd3 |
homeo box D3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXD3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:61,650,569...61,670,285
Ensembl chr 3:61,658,245...61,670,282
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
increases expression |
EXP |
diisobutyl phthalate results in increased expression of HSD17B3 mRNA |
CTD |
PMID:28655647 |
|
NCBI chr17:1,579,319...1,610,745
Ensembl chr17:1,579,319...1,610,745
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSD3B1 mRNA |
CTD |
PMID:28013214 |
|
|
|
G |
Hspa12a |
heat shock protein family A (Hsp70) member 12A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSPA12A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:279,946,809...280,104,366
Ensembl chr 1:279,946,811...280,015,358
|
|
G |
Ido2 |
indoleamine 2,3-dioxygenase 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of IDO2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr16:72,232,852...72,291,227
Ensembl chr16:72,268,943...72,289,156
|
|
G |
Insl3 |
insulin-like 3 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of INSL3 mRNA |
CTD |
PMID:22112501 |
|
NCBI chr16:20,120,753...20,122,702
Ensembl chr16:20,121,352...20,122,696
|
|
G |
Kif5c |
kinesin family member 5C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of KIF5C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:35,014,157...35,257,417
Ensembl chr 3:35,014,538...35,257,407
|
|
G |
L1cam |
L1 cell adhesion molecule |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of L1CAM mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:156,901,244...156,928,064
Ensembl chr X:156,909,913...156,928,057
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LCN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Lonrf2 |
LON peptidase N-terminal domain and ring finger 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LONRF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:45,468,001...45,506,448
Ensembl chr 9:45,466,688...45,505,767
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of LPL mRNA |
CTD |
PMID:30768133 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Lrrc4b |
leucine rich repeat containing 4B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LRRC4B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:100,434,418...100,468,914
Ensembl chr 1:100,447,998...100,468,868
|
|
G |
Lynx1 |
Ly6/neurotoxin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LYNX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:115,982,877...115,988,121
Ensembl chr 7:115,982,876...115,988,090
|
|
G |
Map6 |
microtubule-associated protein 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAP6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:164,225,776...164,292,094
Ensembl chr 1:164,225,934...164,292,093
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAPT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Mir141 |
microRNA 141 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR141 |
CTD |
PMID:31199487 |
|
NCBI chr 4:157,236,346...157,236,439
Ensembl chr 4:157,236,346...157,236,439
|
|
G |
Mir184 |
microRNA 184 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR184 |
CTD |
PMID:31199487 |
|
NCBI chr 8:97,175,657...97,175,733
Ensembl chr 8:97,175,657...97,175,733
|
|
G |
Mllt11 |
MLLT11, transcription factor 7 cofactor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MLLT11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:196,392,936...196,402,106
Ensembl chr 2:196,392,938...196,402,106
|
|
G |
Ncs1 |
neuronal calcium sensor 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NCS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:10,556,250...10,602,672
Ensembl chr 3:10,553,589...10,602,672
|
|
G |
Ndrg4 |
NDRG family member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NDRG4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:9,766,439...9,802,396
Ensembl chr19:9,766,439...9,801,942
|
|
G |
Nefh |
neurofilament heavy |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:85,181,572...85,191,557
Ensembl chr14:85,181,572...85,191,557
|
|
G |
Nefl |
neurofilament light |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFL mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:44,799,378...44,803,251
Ensembl chr15:44,799,334...44,804,574
|
|
G |
Nell1 |
neural EGFL like 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NELL1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:105,348,577...106,218,970
Ensembl chr 1:105,349,069...106,218,958
|
|
G |
Ngfr |
nerve growth factor receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NGFR mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:83,389,828...83,408,061
Ensembl chr10:83,389,847...83,408,061
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
diisobutyl phthalate results in increased activity of NR1I2 protein alternative form |
CTD |
PMID:21227907 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions increases activity affects binding |
ISO |
[diisobutyl phthalate co-treated with Androstanols] results in increased activity of NR1I3 protein alternative form diisobutyl phthalate results in increased activity of NR1I3 protein alternative form diisobutyl phthalate binds to NR1I3 protein |
CTD |
PMID:21227907 PMID:25938866 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Nrxn2 |
neurexin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NRXN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:221,792,191...221,908,047
Ensembl chr 1:221,792,221...221,908,049
|
|
G |
Nsg1 |
neuronal vesicle trafficking associated 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:77,380,264...77,402,007
Ensembl chr14:77,380,262...77,401,996
|
|
G |
Nsg2 |
neuronal vesicle trafficking associated 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:15,867,885...15,928,169
Ensembl chr10:15,867,887...15,928,169
|
|
G |
Olfm1 |
olfactomedin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of OLFM1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:6,761,031...6,798,739
Ensembl chr 3:6,773,813...6,798,737
|
|
G |
Pcp4 |
Purkinje cell protein 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PCP4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:36,851,035...36,912,272
Ensembl chr11:36,851,038...36,912,229
|
|
G |
Plppr3 |
phospholipid phosphatase related 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLPPR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:12,652,555...12,663,825
Ensembl chr 7:12,652,415...12,663,819
|
|
G |
Pls1 |
plastin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:103,557,361...103,659,625
Ensembl chr 8:103,557,364...103,608,913
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPARA mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression increases activity |
ISO |
diisobutyl phthalate binds to and results in increased activity of PPARG protein diisobutyl phthalate results in increased expression of PPARG protein diisobutyl phthalate results in increased activity of PPARG protein |
CTD |
PMID:24155963 PMID:26172262 PMID:27633901 PMID:29061543 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppp2r2b |
protein phosphatase 2, regulatory subunit B, beta |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPP2R2B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:36,985,709...37,421,383
Ensembl chr18:36,985,714...37,245,809
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRIMA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:127,075,954...127,127,985
Ensembl chr 6:127,075,954...127,127,413
|
|
G |
Prph |
peripherin |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRPH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:140,742,406...140,746,197
Ensembl chr 7:140,742,418...140,746,197
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGES mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:9,727,408...9,738,752
Ensembl chr 3:9,727,408...9,738,752
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
|
|
G |
Ptprn |
protein tyrosine phosphatase, receptor type, N |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTPRN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:82,446,626...82,462,314
Ensembl chr 9:82,446,633...82,461,903
|
|
G |
Qsox1 |
quiescin sulfhydryl oxidase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of QSOX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:73,423,396...73,460,890
Ensembl chr13:73,423,397...73,460,935
|
|
G |
Rab3b |
RAB3B, member RAS oncogene family |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:128,501,789...128,568,170
Ensembl chr 5:128,501,847...128,568,188
|
|
G |
Rab6b |
RAB6B, member RAS oncogene family |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB6B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:111,600,375...111,668,817
Ensembl chr 8:111,600,532...111,668,808
|
|
G |
Rassf4 |
Ras association domain family member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RASSF4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:148,769,092...148,804,295
Ensembl chr 4:148,769,096...148,803,988
|
|
G |
Resp18 |
regulated endocrine-specific protein 18 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RESP18 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:82,470,794...82,477,136
Ensembl chr 9:82,470,759...82,477,181
|
|
G |
Rnf183 |
ring finger protein 183 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of RNF183 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:78,283,722...78,292,729
Ensembl chr 5:78,284,879...78,285,451
|
|
G |
Rtn1 |
reticulon 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:94,951,016...95,177,477
Ensembl chr 6:94,951,020...95,061,174
|
|
G |
Rtn4r |
reticulon 4 receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN4R mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:86,992,665...87,017,091
Ensembl chr11:86,992,399...87,017,115
|
|
G |
Rxrg |
retinoid X receptor gamma |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of RXRG mRNA |
CTD |
PMID:22112501 |
|
NCBI chr13:85,818,473...85,868,555
Ensembl chr13:85,818,427...85,868,552
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of SCARB1 mRNA |
CTD |
PMID:22112501 PMID:28655647 |
|
NCBI chr12:36,694,952...36,761,445
Ensembl chr12:36,694,960...36,761,455
|
|
G |
Scg3 |
secretogranin III |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCG3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:82,582,352...82,641,536
Ensembl chr 8:82,582,352...82,641,536
|
|
G |
Scn3b |
sodium voltage-gated channel beta subunit 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCN3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:44,136,413...44,159,011
Ensembl chr 8:44,136,496...44,159,010
|
|
G |
Scrn1 |
secernin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCRN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:84,678,978...84,740,701
Ensembl chr 4:84,678,975...84,740,909
|
|
G |
Sh3gl3 |
SH3 domain containing GRB2 like 3, endophilin A3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3GL3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:144,069,641...144,200,402
Ensembl chr 1:144,069,638...144,200,397
|
|
G |
Sh3tc2 |
SH3 domain and tetratricopeptide repeats 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3TC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:57,286,266...57,403,926
Ensembl chr18:57,286,322...57,347,577
|
|
G |
Shc2 |
SHC adaptor protein 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SHC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:12,948,952...12,971,174
Ensembl chr 7:12,948,952...12,971,174
|
|
G |
Slc13a2 |
solute carrier family 13 member 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC13A2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:65,664,665...65,692,046
Ensembl chr10:65,664,667...65,692,023
|
|
G |
Slc29a4 |
solute carrier family 29 member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC29A4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:13,914,114...13,924,511
Ensembl chr12:13,914,114...13,924,531
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC5A7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:5,294,377...5,330,822
Ensembl chr 9:5,294,381...5,330,815
|
|
G |
Smim24 |
small integral membrane protein 24 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SMIM24 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:11,182,975...11,187,222
Ensembl chr 7:11,183,570...11,186,130
|
|
G |
Snhg11 |
small nucleolar RNA host gene 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SNHG11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:154,862,717...154,870,691
Ensembl chr 3:154,863,072...154,869,460
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SOD1 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
increases expression |
EXP |
diisobutyl phthalate results in increased expression of SOX9 mRNA |
CTD |
PMID:22112501 |
|
NCBI chr10:101,288,528...101,294,030
Ensembl chr10:101,288,489...101,293,379
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in decreased expression of STAR mRNA; diisobutyl phthalate results in decreased expression of STAR protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STAR mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of STAR mRNA |
CTD |
PMID:16458459 PMID:21633115 PMID:22112501 PMID:28013214 PMID:28655647 PMID:30802670 |
|
NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
|
|
G |
Stk32c |
serine/threonine kinase 32C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STK32C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:211,440,335...211,520,699
Ensembl chr 1:211,440,335...211,520,699
|
|
G |
Stmn4 |
stathmin 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STMN4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:43,007,901...43,025,852
Ensembl chr15:43,007,908...43,025,852
|
|
G |
Syt11 |
synaptotagmin 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SYT11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:188,112,301...188,138,180
Ensembl chr 2:188,112,286...188,138,177
|
|
G |
Syt5 |
synaptotagmin 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SYT5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:72,859,806...72,867,934
Ensembl chr 1:72,860,218...72,867,930
|
|
G |
Tbx2 |
T-box transcription factor 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TBX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:73,278,932...73,290,764
Ensembl chr10:73,279,119...73,289,921
|
|
G |
Tcf23 |
transcription factor 23 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TCF23 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:26,763,159...26,772,074
Ensembl chr 6:26,762,761...26,771,164
|
|
G |
Tcte1 |
t-complex-associated testis expressed 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TCTE1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:17,847,866...17,867,276
Ensembl chr 9:17,846,364...17,866,927
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
diisobutyl phthalate binds to and results in decreased activity of THRB protein |
CTD |
PMID:27633901 |
|
NCBI chr15:8,890,578...9,239,815
Ensembl chr15:8,890,578...9,086,282
|
|
G |
Tmeff2 |
transmembrane protein with EGF-like and two follistatin-like domains 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEFF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:55,379,130...55,673,704
Ensembl chr 9:55,384,100...55,673,829
|
|
G |
Tmem130 |
transmembrane protein 130 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM130 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:11,814,071...11,840,100
Ensembl chr12:11,814,071...11,840,100
|
|
G |
Tmem35a |
transmembrane protein 35A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM35A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:105,134,498...105,145,346
Ensembl chr X:105,134,498...105,145,345
|
|
G |
Tmem63c |
transmembrane protein 63c |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM63C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:111,044,099...111,120,659
Ensembl chr 6:111,049,559...111,120,799
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TRPC6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:6,811,543...6,917,534
Ensembl chr 8:6,811,543...6,917,535
|
|
G |
Ttyh1 |
tweety family member 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TTYH1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:73,734,614...73,753,157
Ensembl chr 1:73,734,624...73,753,128
|
|
G |
Tubb2b |
tubulin, beta 2B class IIb |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB2B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:31,441,640...31,444,687
Ensembl chr17:31,441,630...31,482,759
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:56,220,759...56,229,813
Ensembl chr19:56,220,755...56,229,813
|
|
G |
Tubb4a |
tubulin, beta 4A class IVa |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB4A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:9,961,020...9,968,420
Ensembl chr 9:9,961,021...9,968,486
|
|
G |
Ubash3b |
ubiquitin associated and SH3 domain containing, B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of UBASH3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:45,224,053...45,375,450
Ensembl chr 8:45,223,992...45,375,435
|
|
G |
Ubxn11 |
UBX domain protein 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of UBXN11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:152,332,993...152,356,647
Ensembl chr 5:152,333,043...152,356,890
|
|
G |
Wnt6 |
Wnt family member 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WNT6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:82,033,543...82,047,172
Ensembl chr 9:82,033,543...82,047,166
|
|
G |
Wnt9b |
Wnt family member 9B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WNT9B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:91,785,892...91,808,061
Ensembl chr10:91,785,893...91,807,937
|
|
G |
Wt1 |
WT1 transcription factor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:95,133,221...95,180,574
Ensembl chr 3:95,133,713...95,180,564
|
|
G |
Zcchc12 |
zinc finger CCHC-type containing 12 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ZCCHC12 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:122,808,581...122,811,790
Ensembl chr X:122,808,605...122,811,789
|
|
G |
Zfat |
zinc finger and AT hook domain containing |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ZFAT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:109,037,777...109,207,511
Ensembl chr 7:109,037,845...109,205,354
|
|
G |
Zp2 |
zona pellucida glycoprotein 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ZP2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:189,899,906...189,911,650
Ensembl chr 1:189,899,892...189,911,650
|
|
|
G |
Atg13 |
autophagy related 13 |
multiple interactions |
ISO |
ATG13 protein inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]; ATG13 protein promotes the reaction [bafilomycin A inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]]; Nitrogen deficiency inhibits the reaction [ATG13 protein results in increased expression of ULK1 protein]; Nitrogen deficiency promotes the reaction [ATG13 protein results in decreased expression of SQSTM1 protein] |
CTD |
PMID:27629431 |
|
NCBI chr 3:80,580,549...80,614,554
Ensembl chr 3:80,581,247...80,601,410
|
|
G |
Atg4b |
autophagy related 4B, cysteine peptidase |
decreases expression |
ISO |
Nitrogen deficiency results in decreased expression of ATG4B protein |
CTD |
PMID:27629431 |
|
NCBI chr 9:100,888,457...100,920,123
Ensembl chr 9:100,888,501...100,918,637
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions |
ISO |
ATG7 protein inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]; ATG7 protein promotes the reaction [bafilomycin A inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]] |
CTD |
PMID:27629431 |
|
NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of CCL2 protein |
CTD |
PMID:30711708 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of CCL5 protein |
CTD |
PMID:30711708 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO |
[Nanotubes, Carbon co-treated with Nitrogen] results in increased expression of CDK4 protein |
CTD |
PMID:25797581 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of CSF2 protein |
CTD |
PMID:30711708 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Csf3 |
colony stimulating factor 3 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of CSF3 protein |
CTD |
PMID:30711708 |
|
NCBI chr10:86,616,785...86,619,160
Ensembl chr10:86,616,785...86,619,157
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of CXCL1 protein |
CTD |
PMID:30711708 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of CXCL1 protein |
CTD |
PMID:30711708 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Grk1 |
G protein-coupled receptor kinase 1 |
multiple interactions |
ISO |
[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of GRK1 mRNA; Octreotide affects the reaction [SSTR1 protein affects the reaction [[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of GRK1 mRNA]]; Octreotide inhibits the reaction [[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of GRK1 mRNA]; SSTR1 protein affects the reaction [[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of GRK1 mRNA] |
CTD |
PMID:18624922 |
|
NCBI chr16:81,153,489...81,165,442
Ensembl chr16:81,153,489...81,165,442
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of IL6 protein |
CTD |
PMID:30711708 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:30711708 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:30711708 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mif |
macrophage migration inhibitory factor |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of MIF protein |
CTD |
PMID:30711708 |
|
NCBI chr20:13,715,219...13,732,980
Ensembl chr20:13,732,198...13,732,859
|
|
G |
Rgs1 |
regulator of G-protein signaling 1 |
multiple interactions |
ISO |
[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of RGS1 mRNA; Octreotide inhibits the reaction [[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of RGS1 mRNA]; SSTR1 protein affects the reaction [[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of RGS1 mRNA] |
CTD |
PMID:18624922 |
|
NCBI chr13:61,066,196...61,070,772
Ensembl chr13:61,066,153...61,070,599
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[Silver Compounds binds to [Nitrogen binds to titanium dioxide]] which results in increased secretion of SERPINE1 protein |
CTD |
PMID:30711708 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions decreases expression |
ISO |
bafilomycin A inhibits the reaction [Nitrogen deficiency results in decreased expression of SQSTM1 protein]; Nitrogen deficiency promotes the reaction [ATG13 protein results in decreased expression of SQSTM1 protein] |
CTD |
PMID:27629431 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Sstr1 |
somatostatin receptor 1 |
multiple interactions |
ISO |
Octreotide affects the reaction [SSTR1 protein affects the reaction [[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of GRK1 mRNA]]; SSTR1 protein affects the reaction [[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of GRK1 mRNA]; SSTR1 protein affects the reaction [[Nitrogen co-treated with Iodoacetic Acid] results in increased expression of RGS1 mRNA] |
CTD |
PMID:18624922 |
|
NCBI chr 6:79,252,914...79,258,611
Ensembl chr 6:79,254,339...79,258,611
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
EXP |
Nitrogen inhibits the reaction [myricetin results in decreased activity of TXNRD1 protein modified form]; Nitrogen inhibits the reaction [Quercetin results in decreased activity of TXNRD1 protein modified form] |
CTD |
PMID:16618767 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions increases expression |
ISO |
Antimycin A inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]; ATG13 protein inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]; ATG13 protein promotes the reaction [bafilomycin A inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]]; ATG7 protein inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]; ATG7 protein promotes the reaction [bafilomycin A inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]]; bafilomycin A inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]; Nitrogen deficiency inhibits the reaction [Antimycin A results in increased expression of ULK1 protein]; Nitrogen deficiency inhibits the reaction [ATG13 protein results in increased expression of ULK1 protein]; Nitrogen deficiency results in decreased expression of and results in decreased phosphorylation of and results in increased cleavage of and affects the localization of ULK1 protein Nitrogen deficiency results in increased expression of ULK1 mRNA |
CTD |
PMID:27629431 |
|
NCBI chr12:51,908,105...51,934,704
Ensembl chr12:51,908,448...51,934,702
|
|
|
G |
Cntf |
ciliary neurotrophic factor |
multiple interactions decreases activity |
ISO |
Nitrous Oxide inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT1 protein]; Nitrous Oxide inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT3 protein] Nitrous Oxide inhibits the reaction [CNTF protein results in increased activity of STAT3 protein] Nitrous Oxide results in decreased activity of CNTF protein |
CTD |
PMID:15748169 |
|
NCBI chr 1:229,599,009...229,601,032
Ensembl chr 1:229,599,009...229,601,032
|
|
G |
Gabra4 |
gamma-aminobutyric acid type A receptor subunit alpha 4 |
multiple interactions |
ISO |
[Isoflurane co-treated with Nitrous Oxide] affects the expression of GABRA4 mRNA |
CTD |
PMID:16733821 |
|
NCBI chr14:39,154,072...39,230,994
Ensembl chr14:39,154,529...39,231,695
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions |
ISO |
GRIN2A protein affects the susceptibility to [Nitrous Oxide co-treated with sevoflurane] |
CTD |
PMID:15731593 |
|
NCBI chr10:5,707,806...6,123,568
Ensembl chr10:5,930,298...6,119,990
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
decreases activity |
ISO |
Nitrous Oxide results in decreased activity of MTR protein |
CTD |
PMID:18472229 |
|
NCBI chr17:66,210,444...66,295,014
Ensembl chr17:66,210,461...66,295,014
|
|
G |
Pla2g7 |
phospholipase A2 group VII |
affects expression |
ISO |
Nitrous Oxide affects the expression of PLA2G7 |
CTD |
PMID:21356620 |
|
NCBI chr 9:19,935,754...19,978,013
Ensembl chr 9:19,935,768...19,978,013
|
|
G |
Pomc |
proopiomelanocortin |
increases secretion |
EXP |
Nitrous Oxide results in increased secretion of POMC protein |
CTD |
PMID:2846107 |
|
NCBI chr 6:28,382,937...28,388,771
Ensembl chr 6:28,382,962...28,388,967
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Nitrous Oxide inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT1 protein] |
CTD |
PMID:15748169 |
|
NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
Nitrous Oxide inhibits the reaction [CNTF protein results in increased activity of STAT3 protein] Nitrous Oxide inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT3 protein] |
CTD |
PMID:15748169 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
|
G |
Arg1 |
arginase 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ARG1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CYP1A1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CYP2C19 protein |
CTD |
PMID:32194361 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CYP7A1 mRNA; fenpyroximate results in decreased expression of CYP7A1 protein |
CTD |
PMID:32194361 |
|
NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
fenpyroximate inhibits the reaction [Estradiol results in increased activity of ESR2 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
ISO |
fenpyroximate inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; fenpyroximate inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:222,168,729...222,178,842
Ensembl chr 1:222,168,730...222,178,725
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of G6PC1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases activity |
ISO |
fenpyroximate results in increased activity of NFE2L2 protein |
CTD |
PMID:30818834 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nmnat3 |
nicotinamide nucleotide adenylyltransferase 3 |
decreases response to substance |
ISO |
NMNAT3 protein results in decreased susceptibility to fenpyroximate |
CTD |
PMID:18463239 |
|
NCBI chr 8:106,317,038...106,429,535
Ensembl chr 8:106,317,124...106,429,522
|
|
G |
Park7 |
Parkinsonism associated deglycase |
decreases response to substance |
ISO |
PARK7 protein results in decreased susceptibility to fenpyroximate |
CTD |
PMID:21219333 |
|
NCBI chr 5:167,982,438...168,004,724
Ensembl chr 5:167,982,439...168,004,724
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
fenpyroximate inhibits the reaction [Promegestone results in increased activity of PGR protein] |
CTD |
PMID:30818834 |
|
NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
fenpyroximate inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Snca |
synuclein alpha |
increases response to substance |
ISO |
SNCA protein results in increased susceptibility to fenpyroximate |
CTD |
PMID:16239214 |
|
NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
|
|
G |
Thra |
thyroid hormone receptor alpha |
increases activity |
ISO |
fenpyroximate results in increased activity of THRA protein |
CTD |
PMID:20143881 |
|
NCBI chr10:86,657,285...86,684,935
Ensembl chr10:86,657,285...86,684,933
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
fluvalinate analog promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] |
CTD |
PMID:25684042 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
affects binding |
ISO |
fluvalinate binds to CDK2 protein |
CTD |
PMID:32278787 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
affects binding |
ISO |
fluvalinate binds to CYP3A4 protein |
CTD |
PMID:32278787 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
affects binding |
ISO |
fluvalinate binds to ERBB2 protein |
CTD |
PMID:32278787 |
|
NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
affects binding |
ISO |
fluvalinate binds to FGFR2 protein |
CTD |
PMID:32278787 |
|
NCBI chr 1:200,590,951...200,696,946
Ensembl chr 1:200,590,953...200,696,928
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
affects binding |
ISO |
fluvalinate binds to MMP9 protein |
CTD |
PMID:32278787 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
affects binding |
ISO |
fluvalinate binds to NQO1 protein |
CTD |
PMID:32278787 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
fluvalinate inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
fluvalinate binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:21115097 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
affects binding |
ISO |
fluvalinate binds to PPARD protein |
CTD |
PMID:32278787 |
|
NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
|
|
G |
Rora |
RAR-related orphan receptor A |
affects binding |
ISO |
fluvalinate binds to RORA protein |
CTD |
PMID:32278787 |
|
NCBI chr 8:75,515,886...75,616,477
Ensembl chr 8:75,516,904...75,607,212
|
|
G |
Rorc |
RAR-related orphan receptor C |
affects binding |
ISO |
fluvalinate binds to RORC protein |
CTD |
PMID:32278787 |
|
NCBI chr 2:195,612,471...195,636,797
Ensembl chr 2:195,617,021...195,637,630
|
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ACAT1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:58,166,990...58,195,884
Ensembl chr 8:58,166,990...58,195,884
|
|
G |
Acsf2 |
acyl-CoA synthetase family member 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ACSF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:82,284,719...82,326,771
Ensembl chr10:82,284,720...82,326,771
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ACSS2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:151,032,925...151,075,856
Ensembl chr 3:151,032,952...151,075,856
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ADGRG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:10,423,534...10,460,674
Ensembl chr19:10,423,501...10,460,674
|
|
G |
Adora2b |
adenosine A2B receptor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ADORA2B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:48,569,563...48,586,366
Ensembl chr10:48,569,555...48,586,365
|
|
G |
Ahnak2 |
AHNAK nucleoprotein 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AHNAK2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:137,335,273...137,380,219
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of AKAP12 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:40,816,130...40,906,582
Ensembl chr 1:40,816,107...40,906,581
|
|
G |
Aldh1l2 |
aldehyde dehydrogenase 1 family, member L2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ALDH1L2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:26,375,866...26,425,838
Ensembl chr 7:26,375,866...26,425,108
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ALDH7A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:51,619,007...51,651,267
Ensembl chr18:51,619,007...51,651,267
|
|
G |
Aldh9a1 |
aldehyde dehydrogenase 9 family, member A1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ALDH9A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:85,580,828...85,597,497
Ensembl chr13:85,580,828...85,597,493
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ALDOC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:65,586,504...65,590,093
Ensembl chr10:65,586,504...65,590,126
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:18,627,814...18,634,043
Ensembl chr 7:18,627,808...18,634,079
|
|
G |
Anxa11 |
annexin A11 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ANXA11 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:3,867,193...3,912,043
Ensembl chr16:3,867,208...3,912,148
|
|
G |
Anxa2 |
annexin A2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ANXA2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594
|
|
G |
Anxa8 |
annexin A8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ANXA8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:10,417,174...10,432,388
Ensembl chr16:10,417,185...10,432,393
|
|
G |
Aox1 |
aldehyde oxidase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AOX1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
|
|
G |
Ap1b1 |
adaptor related protein complex 1 subunit beta 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AP1B1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:85,230,652...85,281,806
Ensembl chr14:85,230,648...85,281,803
|
|
G |
Ap1s2 |
adaptor related protein complex 1 subunit sigma 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AP1S2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:32,329,883...32,376,301
Ensembl chr X:32,329,598...32,355,307
|
|
G |
Ap2s1 |
adaptor related protein complex 2 subunit sigma 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AP2S1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:78,671,238...78,682,847
Ensembl chr 1:78,671,121...78,682,871
|
|
G |
Ap3d1 |
adaptor related protein complex 3 subunit delta 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of AP3D1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:11,838,639...11,873,992
Ensembl chr 7:11,838,639...11,873,984
|
|
G |
Apbb3 |
amyloid beta precursor protein binding family B member 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of APBB3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:29,497,865...29,504,995
Ensembl chr18:29,497,863...29,504,995
|
|
G |
Arap3 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARAP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:31,112,083...31,138,142
Ensembl chr18:31,112,623...31,136,200
|
|
G |
Arhgef16 |
Rho guanine nucleotide exchange factor 16 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ARHGEF16 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:171,626,450...171,649,124
Ensembl chr 5:171,624,796...171,648,563
|
|
G |
Arid5b |
AT-rich interaction domain 5B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARID5B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:21,713,900...21,881,193
Ensembl chr20:21,564,975...21,880,715
|
|
G |
Arl4a |
ADP-ribosylation factor like GTPase 4A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARL4A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:59,945,926...59,950,586
Ensembl chr 6:59,948,577...59,950,586
|
|
G |
Arl5a |
ADP-ribosylation factor like GTPase 5A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARL5A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:37,922,544...37,947,434
Ensembl chr 3:37,924,793...37,947,283
|
|
G |
Atp5mg |
ATP synthase membrane subunit g |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP5L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:49,220,441...49,227,273
Ensembl chr 8:49,220,443...49,227,273
|
|
G |
Atp5pf |
ATP synthase peripheral stalk subunit F6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP5J mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:24,286,806...24,294,419
Ensembl chr11:24,286,787...24,294,179
|
|
G |
Atp6v0b |
ATPase H+ transporting V0 subunit B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ATP6V0B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:136,718,352...136,719,868
Ensembl chr 5:136,718,352...136,721,379
|
|
G |
Atp6v0e1 |
ATPase H+ transporting V0 subunit e1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP6V0E1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:16,769,857...16,792,930
Ensembl chr10:16,769,666...16,792,909
|
|
G |
Atp8b2 |
ATPase phospholipid transporting 8B2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP8B2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:189,285,961...189,306,947
Ensembl chr 2:189,285,953...189,307,108
|
|
G |
Atp9a |
ATPase phospholipid transporting 9A (putative) |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ATP9A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:165,405,588...165,511,104
Ensembl chr 3:165,412,803...165,477,771
|
|
G |
B4galt5 |
beta-1,4-galactosyltransferase 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of B4GALT5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:164,039,731...164,055,561
Ensembl chr 3:164,039,731...164,095,878
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BCAR3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:226,563,050...226,679,449
Ensembl chr 2:226,563,050...226,679,438
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BCKDK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:199,351,628...199,356,299
Ensembl chr 1:199,351,628...199,356,881
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BHLHE40 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:140,703,619...140,709,319
Ensembl chr 4:140,703,619...140,709,319
|
|
G |
Bik |
BCL2-interacting killer |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of BIK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BNIP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Cacybp |
calcyclin binding protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CACYBP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:77,948,771...77,959,089
Ensembl chr13:77,948,771...77,959,110
|
|
G |
Card10 |
caspase recruitment domain family, member 10 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CARD10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:119,998,639...120,028,632
Ensembl chr 7:119,999,472...120,027,026
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CASP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
|
|
G |
Cav2 |
caveolin 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CAV2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:44,573,264...44,580,640
Ensembl chr 4:44,573,264...44,580,638
|
|
G |
Ccdc12 |
coiled-coil domain containing 12 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC12 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:118,925,682...118,977,038
Ensembl chr 8:118,926,478...118,977,051
|
|
G |
Ccdc92 |
coiled-coil domain containing 92 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC92 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:37,210,735...37,237,848
Ensembl chr12:37,211,316...37,237,848
|
|
G |
Ccdc93 |
coiled-coil domain containing 93 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC93 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:37,400,455...37,473,973
Ensembl chr13:37,400,476...37,468,840
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCN2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CCND2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Cd24 |
CD24 molecule |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CD24 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:48,335,540...48,340,847
Ensembl chr20:48,335,540...48,340,846
|
|
G |
Cd63 |
Cd63 molecule |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CD63 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:3,320,250...3,335,583
Ensembl chr 7:3,320,103...3,335,582
|
|
G |
Cd99l2 |
CD99 molecule-like 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CD99L2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:5,265,257...5,311,232
Ensembl chr15:5,265,307...5,311,233 Ensembl chr15:5,265,307...5,311,233
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CDC20 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:137,260,728...137,264,931
Ensembl chr 5:137,260,739...137,265,015
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which affects the expression of CDH1 mRNA; [[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CDH1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdh3 |
cadherin 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CDH3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:38,668,957...38,719,801
Ensembl chr19:38,669,230...38,719,677
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CDKN1A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cenpa |
centromere protein A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CENPA mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:27,072,259...27,080,863
Ensembl chr 6:27,072,166...27,080,856
|
|
G |
Cenpf |
centromere protein F |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CENPF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:108,132,499...108,178,609
Ensembl chr13:108,132,499...108,178,609
|
|
G |
Cep192 |
centrosomal protein 192 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CEP192 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:63,572,084...63,656,302
Ensembl chr18:63,524,452...63,656,286
|
|
G |
Cfap251 |
cilia and flagella associated protein 251 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CFAP251 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:38,708,915...38,781,598
Ensembl chr12:38,709,595...38,782,010
|
|
G |
Chd9 |
chromodomain helicase DNA binding protein 9 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CHD9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:17,364,969...17,517,757
Ensembl chr19:17,366,828...17,494,585
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
ISO |
isobutyl alcohol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr15:42,808,897...42,825,179
Ensembl chr15:42,808,897...42,825,179
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
ISO |
isobutyl alcohol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr 8:59,610,489...59,629,073
Ensembl chr 8:59,609,693...59,629,133
|
|
G |
Chtop |
chromatin target of PRMT1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CHTOP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:189,887,850...189,900,079
Ensembl chr 2:189,887,857...189,899,325
|
|
G |
Cited4 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CITED4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:139,597,731...139,598,622
Ensembl chr 5:139,597,731...139,598,622
|
|
G |
Cklf |
chemokine-like factor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CKLF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:903,609...914,880
Ensembl chr19:906,411...914,880
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CKS2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:13,587,664...13,593,423
Ensembl chr17:13,587,665...13,593,423
|
|
G |
Clcn6 |
chloride voltage-gated channel 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CLCN6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:164,811,815...164,844,554
Ensembl chr 5:164,811,816...164,844,586
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CLDN1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:77,815,216...77,830,373
Ensembl chr11:77,815,181...77,830,416
|
|
G |
Cnn2 |
calponin 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CNN2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:12,782,459...12,787,977
Ensembl chr 7:12,782,491...12,787,750
|
|
G |
Cnpy4 |
canopy FGF signaling regulator 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CNPY4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:19,329,027...19,335,126
Ensembl chr12:19,328,957...19,335,119
|
|
G |
Coa3 |
cytochrome C oxidase assembly factor 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC56 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:89,198,750...89,199,731
Ensembl chr10:89,198,749...89,199,736
|
|
G |
Commd1 |
copper metabolism domain containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COMMD1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:107,664,321...107,759,974
Ensembl chr14:107,664,255...107,760,191
|
|
G |
Coq3 |
coenzyme Q3 methyltransferase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COQ3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:36,024,673...36,056,664
Ensembl chr 5:36,024,649...36,056,669
|
|
G |
Coq5 |
coenzyme Q5, methyltransferase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COQ5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:47,078,753...47,095,438
Ensembl chr12:47,078,753...47,095,438
|
|
G |
Cotl1 |
coactosin-like F-actin binding protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of COTL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:52,465,074...52,499,433
Ensembl chr19:52,465,087...52,499,433
|
|
G |
Cox16 |
cytochrome c oxidase assembly factor COX16 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COX16 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:105,195,387...105,214,366
Ensembl chr 6:105,201,395...105,214,329
|
|
G |
Cox7c |
cytochrome c oxidase subunit 7C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of COX7C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:14,699,878...14,701,903
Ensembl chr 2:14,699,882...14,701,903
|
|
G |
Cpa4 |
carboxypeptidase A4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CPA4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:57,883,849...57,907,826
Ensembl chr 4:57,883,849...57,907,826
|
|
G |
Cpd |
carboxypeptidase D |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CPD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:63,325,764...63,389,811
Ensembl chr10:63,325,199...63,389,817
|
|
G |
Creb3l2 |
cAMP responsive element binding protein 3-like 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CREB3L2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:64,869,285...64,981,519
Ensembl chr 4:64,869,026...64,981,384
|
|
G |
Cript |
CXXC repeat containing interactor of PDZ3 domain |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CRIPT mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:10,594,147...10,602,103
Ensembl chr 6:10,594,122...10,602,085
|
|
G |
Crispld2 |
cysteine-rich secretory protein LCCL domain containing 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CRISPLD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:52,647,038...52,705,118
Ensembl chr19:52,647,070...52,705,131
|
|
G |
Csk |
C-terminal Src kinase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CSK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:62,405,714...62,424,707
Ensembl chr 8:62,405,715...62,424,303
|
|
G |
Csnk1e |
casein kinase 1, epsilon |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CSNK1E mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:120,651,976...120,675,559
Ensembl chr 7:120,651,881...120,672,359
|
|
G |
Cul1 |
cullin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CUL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:77,211,814...77,283,369
Ensembl chr 4:77,211,692...77,280,250
|
|
G |
Cuta |
cutA divalent cation tolerance homolog |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CUTA mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:5,532,024...5,533,640
Ensembl chr20:5,532,024...5,533,620
|
|
G |
Cwc15 |
CWC15 spliceosome-associated protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CWC15 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:12,994,131...13,004,958
Ensembl chr 8:12,994,155...13,004,957
|
|
G |
Cxxc5 |
CXXC finger protein 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CXXC5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:28,626,386...28,656,916
Ensembl chr18:28,653,592...28,656,937
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CYBA mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
|
|
G |
Cygb |
cytoglobin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CYGB mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:105,618,325...105,628,091
Ensembl chr10:105,618,326...105,628,091
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CYP1A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp4x1 |
cytochrome P450, family 4, subfamily x, polypeptide 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CYP4X1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:133,929,532...133,959,447
Ensembl chr 5:133,929,532...133,959,447
|
|
G |
Cysrt1 |
cysteine rich tail 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CYSRT1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:2,458,295...2,462,037
Ensembl chr 3:2,458,295...2,459,385
|
|
G |
Dapk3 |
death-associated protein kinase 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of DAPK3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:11,392,436...11,400,855
Ensembl chr 7:11,392,437...11,400,805
|
|
G |
Dbi |
diazepam binding inhibitor, acyl-CoA binding protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DBI mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:36,147,667...36,156,076
Ensembl chr13:36,117,119...36,174,908
|
|
G |
Dbt |
dihydrolipoamide branched chain transacylase E2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DBT mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:219,563,783...219,592,651
Ensembl chr 2:219,563,783...219,592,650
|
|
G |
Dcaf15 |
DDB1 and CUL4 associated factor 15 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of DCAF15 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:25,212,469...25,219,803
Ensembl chr19:25,212,661...25,220,010
|
|
G |
Dcbld2 |
discoidin, CUB and LCCL domain containing 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DCBLD2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:44,237,814...44,292,884
Ensembl chr11:44,241,111...44,292,884
|
|
G |
Dcp2 |
decapping mRNA 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DCP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:35,489,274...35,671,676
Ensembl chr18:35,489,274...35,672,291
|
|
G |
Dctn5 |
dynactin subunit 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DCTN5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:192,088,709...192,105,421
Ensembl chr 1:192,088,672...192,105,429
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DDIT4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of DDR1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:3,553,430...3,574,959
Ensembl chr20:3,552,929...3,575,780
|
|
G |
Decr2 |
2,4-dienoyl-CoA reductase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DECR2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:15,451,850...15,460,227
Ensembl chr10:15,431,638...15,465,413
|
|
G |
Dennd1a |
DENN domain containing 1A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DENND1A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:22,061,120...22,501,502
Ensembl chr 3:22,058,400...22,500,765
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of DKK1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:248,952,896...248,956,579
Ensembl chr 1:248,895,738...248,898,607
|
|
G |
Dnaaf10 |
dynein axonemal assembly factor 10 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DNAAF10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:100,373,129...100,394,143
Ensembl chr14:100,373,129...100,394,145
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DNAJA1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:57,028,467...57,039,378
Ensembl chr 5:57,028,467...57,039,378
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DNAJB6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:2,711,329...2,774,969
Ensembl chr 4:2,711,385...2,774,890
|
|
G |
Dnase1l1 |
deoxyribonuclease 1-like 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of DNASE1L1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:156,429,521...156,438,066
Ensembl chr X:156,429,585...156,438,066
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EBP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:15,049,394...15,055,782
Ensembl chr X:15,049,462...15,055,781
|
|
G |
Eef1d |
eukaryotic translation elongation factor 1 delta |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of EEF1D mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:116,928,264...116,942,981
Ensembl chr 7:116,928,265...116,936,674
|
|
G |
Efnb1 |
ephrin B1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of EFNB1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:68,891,227...68,904,034
Ensembl chr X:68,891,227...68,904,038
|
|
G |
Efnb2 |
ephrin B2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EFNB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:86,631,151...86,672,050
Ensembl chr16:86,631,064...86,675,049
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of EGR1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ELOVL6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:234,187,490...234,296,124
Ensembl chr 2:234,189,105...234,296,145 Ensembl chr 2:234,189,105...234,296,145
|
|
G |
Elp6 |
elongator acetyltransferase complex subunit 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ELP6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:118,525,770...118,541,074
Ensembl chr 8:118,525,682...118,541,073
|
|
G |
Erh |
ERH, mRNA splicing and mitosis factor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ERH mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:104,280,390...104,290,905
Ensembl chr 6:104,280,408...104,290,579
|
|
G |
Exoc2 |
exocyst complex component 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EXOC2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:34,665,810...34,842,266
Ensembl chr17:34,665,872...34,842,266
|
|
G |
Exosc2 |
exosome component 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EXOSC2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:10,151,734...10,161,997
Ensembl chr 3:10,151,284...10,161,989
|
|
G |
Ezr |
ezrin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of EZR mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:47,287,872...47,331,412
Ensembl chr 1:47,287,874...47,331,412
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of F2RL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:25,222,324...25,235,275
Ensembl chr 2:25,222,328...25,235,275
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of F3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fam217b |
family with sequence similarity 217, member B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FAM217B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:173,953,752...173,961,615
Ensembl chr 3:173,953,869...173,963,629
|
|
G |
Fam98a |
family with sequence similarity 98, member A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FAM98A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:21,051,327...21,065,986
Ensembl chr 6:21,051,327...21,065,986
|
|
G |
Fance |
FA complementation group E |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FANCE mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:7,888,927...7,906,142
Ensembl chr20:7,895,083...7,906,142
|
|
G |
Fancl |
FA complementation group L |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FANCL mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:110,675,306...110,740,880
Ensembl chr14:110,676,090...110,740,317
|
|
G |
Fbxo2 |
F-box protein 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FBXO2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:164,972,483...164,977,912
Ensembl chr 5:164,972,480...164,977,916
|
|
G |
Fbxw5 |
F-box and WD repeat domain containing 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FBXW5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:2,726,705...2,731,213
Ensembl chr 3:2,727,254...2,731,212
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FEZ1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:39,305,128...39,350,270
Ensembl chr 8:39,305,128...39,350,270
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FGFR3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:82,272,322...82,287,739
Ensembl chr14:82,273,070...82,287,706
|
|
G |
Fgl1 |
fibrinogen-like 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FGL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:54,153,086...54,188,120
Ensembl chr16:54,153,054...54,188,181
|
|
G |
Fnbp1 |
formin binding protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FNBP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:9,865,657...9,936,333
Ensembl chr 3:9,861,237...9,936,405
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FOS mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FOSL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
|
|
G |
Foxj2 |
forkhead box J2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FOXJ2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:155,653,446...155,679,815
Ensembl chr 4:155,653,718...155,679,793
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of FOXO3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
Fst |
follistatin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FST mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:46,537,589...46,544,813
Ensembl chr 2:46,538,700...46,544,457
|
|
G |
Ftsj1 |
FtsJ RNA 2'-O-methyltransferase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of FTSJ1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:14,993,685...15,006,010
Ensembl chr X:14,994,016...15,002,074
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GADD45A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Galnt11 |
polypeptide N-acetylgalactosaminyltransferase 11 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GALNT11 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:6,297,255...6,330,765
Ensembl chr 4:6,297,258...6,330,765
|
|
G |
Gbp1 |
guanylate binding protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GBP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:248,343,334...248,423,402
Ensembl chr 2:248,398,917...248,409,570
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GJB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr15:37,377,313...37,394,494
Ensembl chr15:37,377,316...37,383,277
|
|
G |
Gldc |
glycine decarboxylase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GLDC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:248,295,140...248,377,122
Ensembl chr 1:248,297,331...248,377,093
|
|
G |
Glipr2 |
GLI pathogenesis-related 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GLIPR2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:59,415,415...59,446,732
Ensembl chr 5:59,416,076...59,446,647
|
|
G |
Glis3 |
GLIS family zinc finger 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GLIS3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:246,380,816...246,564,385
Ensembl chr 1:246,380,889...246,785,360
|
|
G |
Glmp |
glycosylated lysosomal membrane protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GLMP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:187,697,528...187,701,118
Ensembl chr 2:187,697,523...187,701,118
|
|
G |
Glrx |
glutaredoxin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GLRX mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:2,606,032...2,615,944
Ensembl chr 2:2,605,996...2,615,944
|
|
G |
Gng10 |
G protein subunit gamma 10 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GNG10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:76,182,100...76,189,014
Ensembl chr 5:76,182,121...76,189,013
|
|
G |
Gpc1 |
glypican 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GPC1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:99,998,275...100,026,818
Ensembl chr 9:99,998,275...100,026,818
|
|
G |
Gpd1l |
glycerol-3-phosphate dehydrogenase 1-like |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GPD1L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:122,957,570...122,987,236
Ensembl chr 8:122,954,948...122,987,191
|
|
G |
Gpr137 |
G protein-coupled receptor 137 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GPR137 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:222,194,266...222,197,252
Ensembl chr 1:222,194,266...222,197,252
|
|
G |
Grpel1 |
GrpE-like 1, mitochondrial |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of GRPEL1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:79,458,951...79,464,782
Ensembl chr14:79,458,963...79,464,770
|
|
G |
Gtf2b |
general transcription factor IIB |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GTF2B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:248,709,433...248,727,741
Ensembl chr 2:248,715,281...248,727,741
|
|
G |
Gtf2f1 |
general transcription factor IIF subunit 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GTF2F1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:10,032,806...10,042,392
Ensembl chr 9:10,033,011...10,042,418
|
|
G |
Gtpbp4 |
GTP binding protein 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GTPBP4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:63,111,086...63,145,618
Ensembl chr17:63,110,254...63,145,577
|
|
G |
Gypc |
glycophorin C (Gerbich blood group) |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of GYPC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:25,312,386...25,344,614
Ensembl chr18:25,312,387...25,344,614
|
|
G |
Hirip3 |
HIRA interacting protein 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HIRIP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:198,298,138...198,301,164
Ensembl chr 1:198,298,138...198,301,161
|
|
G |
Hmgb3 |
high mobility group box 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HMGB3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:36,690,190...36,694,329
Ensembl chr17:36,690,249...36,694,325 Ensembl chr14:36,690,249...36,694,325
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HMGCR mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HMGCS1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:52,427,351...52,445,082
Ensembl chr 2:52,431,601...52,445,055
|
|
G |
Hnrnpa3 |
heterogeneous nuclear ribonucleoprotein A3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of HNRNPA3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:62,481,222...62,491,356
Ensembl chr 3:62,481,323...62,487,227
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HNRNPK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:6,664,730...6,676,753
Ensembl chr17:6,665,659...6,676,654
|
|
G |
Hoxb2 |
homeobox B2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HOXB2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:84,200,859...84,203,065
Ensembl chr10:84,200,880...84,202,688
|
|
G |
Hps6 |
HPS6, biogenesis of lysosomal organelles complex 2 subunit 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HPS6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:265,761,818...265,764,427
Ensembl chr 1:265,761,738...265,764,437
|
|
G |
Hsd17b8 |
hydroxysteroid (17-beta) dehydrogenase 8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HSD17B8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:3,817,212...3,819,316
Ensembl chr20:3,817,179...3,819,235
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of HSPA8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of HSPB1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of IL1B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il24 |
interleukin 24 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of IL24 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:47,618,451...47,623,849
Ensembl chr13:47,618,452...47,623,849
|
|
G |
Ino80c |
INO80 complex subunit C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of INO80C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:15,995,005...16,009,639
Ensembl chr18:15,995,000...16,009,710
|
|
G |
Insig1 |
insulin induced gene 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of INSIG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:342,302...350,515
Ensembl chr 4:342,302...350,515
|
|
G |
Itgb4 |
integrin subunit beta 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ITGB4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:104,524,000...104,560,180
Ensembl chr10:104,523,996...104,561,078
|
|
G |
Itgb5 |
integrin subunit beta 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ITGB5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:70,056,500...70,172,164
Ensembl chr11:70,056,500...70,172,372
|
|
G |
Jag2 |
jagged canonical Notch ligand 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of JAG2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:137,711,144...137,733,331
Ensembl chr 6:137,711,155...137,733,026
|
|
G |
Jmjd8 |
jumonji domain containing 8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of JMJD8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:15,195,954...15,198,870
Ensembl chr10:15,195,969...15,198,868
|
|
G |
Jup |
junction plakoglobin |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of JUP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:88,280,517...88,307,451
Ensembl chr10:88,279,632...88,307,412
|
|
G |
Kat8 |
lysine acetyltransferase 8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KAT8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:199,360,645...199,372,925
Ensembl chr 1:199,360,645...199,372,923
|
|
G |
Kb15 |
type II keratin Kb15 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of KRT6C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:143,208,034...143,217,771
Ensembl chr 7:143,208,527...143,217,535
|
|
G |
Klf6 |
Kruppel-like factor 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KLF6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
|
|
G |
Kntc1 |
kinetochore associated 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KNTC1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:38,200,463...38,274,162
Ensembl chr12:38,200,463...38,274,036
|
|
G |
Krba1 |
KRAB-A domain containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KRBA1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:78,024,867...78,046,330
Ensembl chr 4:78,024,765...78,046,066
|
|
G |
Krt16 |
keratin 16 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of KRT16 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:88,149,210...88,152,167
Ensembl chr10:88,149,345...88,152,064
|
|
G |
Krt5 |
keratin 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of KRT5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:143,320,142...143,324,536
Ensembl chr 7:143,316,920...143,453,546
|
|
G |
Krtcap2 |
keratinocyte associated protein 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of KRTCAP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:188,561,548...188,565,544
Ensembl chr 2:188,561,429...188,565,544
|
|
G |
Lamtor4 |
late endosomal/lysosomal adaptor, MAPK and MTOR activator 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LAMTOR4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:19,573,909...19,577,625
Ensembl chr12:19,573,909...19,577,624
|
|
G |
Lbh |
LBH regulator of WNT signaling pathway |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LBH mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:24,154,207...24,184,217
Ensembl chr 6:24,160,226...24,181,866
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LDLR mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
|
|
G |
Lgals1 |
galectin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LGALS1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:120,153,184...120,156,290
Ensembl chr 7:120,153,184...120,156,289
|
|
G |
Lima1 |
LIM domain and actin binding 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of LIMA1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:141,428,113...141,528,447
Ensembl chr 7:141,428,063...141,528,397
|
|
G |
Litaf |
lipopolysaccharide-induced TNF factor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of LITAF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:4,753,546...4,763,272
Ensembl chr10:4,719,713...4,763,510
|
|
G |
Lix1l |
limb and CNS expressed 1 like |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LIX1L mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:198,726,110...198,751,987
Ensembl chr 2:198,726,118...198,751,985
|
|
G |
Lmod3 |
leiomodin 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LMOD3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:129,604,378...129,619,136
Ensembl chr 4:129,604,267...129,619,142
|
|
G |
LOC100912373 |
uncharacterized LOC100912373 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of C8ORF88 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:28,480,029...28,505,430
Ensembl chr 5:28,480,023...28,505,432
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LPIN1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:41,796,214...41,905,149
Ensembl chr 6:41,799,749...41,870,046
|
|
G |
Lrrc20 |
leucine rich repeat containing 20 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LRRC20 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:31,069,406...31,202,502
Ensembl chr20:31,096,214...31,202,514
|
|
G |
Luzp1 |
leucine zipper protein 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LUZP1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:154,831,697...154,907,646
Ensembl chr 5:154,868,534...154,907,634
|
|
G |
Lyrm2 |
LYR motif containing 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of LYRM2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:48,047,913...48,050,191
Ensembl chr 5:48,047,913...48,050,187
|
|
G |
Manf |
mesencephalic astrocyte-derived neurotrophic factor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MANF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:115,623,175...115,626,408
Ensembl chr 8:115,623,178...115,626,380
|
|
G |
Map7d1 |
MAP7 domain containing 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MAP7D1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:144,250,416...144,274,981
Ensembl chr 5:144,250,419...144,274,981
|
|
G |
Mat2b |
methionine adenosyltransferase 2B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MAT2B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:25,832,096...25,848,045
Ensembl chr10:25,832,072...25,847,994
|
|
G |
Mbtps1 |
membrane-bound transcription factor peptidase, site 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MBTPS1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:52,146,507...52,206,310
Ensembl chr19:52,146,808...52,206,310
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MCM7 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:19,306,615...19,313,877
Ensembl chr12:19,306,607...19,314,016
|
|
G |
Med7 |
mediator complex subunit 7 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MED7 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:31,532,190...31,536,405
Ensembl chr10:31,532,250...31,536,405
|
|
G |
Mfsd3 |
major facilitator superfamily domain containing 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MFSD3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:117,763,395...117,765,904
Ensembl chr 7:117,763,783...117,766,464
|
|
G |
Mgarp |
mitochondria-localized glutamic acid-rich protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MGARP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:140,444,963...140,453,719
Ensembl chr 2:140,444,965...140,453,107
|
|
G |
Mgat2 |
alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MGAT2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:91,476,698...91,479,187
Ensembl chr 6:91,476,698...91,479,183
|
|
G |
Mlkl |
mixed lineage kinase domain like pseudokinase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MLKL mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:43,508,416...43,535,050
Ensembl chr19:43,506,976...43,528,851
|
|
G |
Mmachc |
metabolism of cobalamin associated C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MMACHC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:135,555,587...135,561,723
Ensembl chr 5:135,555,565...135,561,914
|
|
G |
Mms19 |
MMS19 homolog, cytosolic iron-sulfur assembly component |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MMS19 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:261,191,646...261,229,070
Ensembl chr 1:261,191,646...261,229,046
|
|
G |
Mpdz |
multiple PDZ domain crumbs cell polarity complex component |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MPDZ mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:99,413,184...99,566,356
Ensembl chr 5:99,413,187...99,566,318
|
|
G |
Mpzl2 |
myelin protein zero-like 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MPZL2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:49,342,067...49,353,080
Ensembl chr 8:49,342,067...49,353,080
|
|
G |
Mrpl32 |
mitochondrial ribosomal protein L32 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MRPL32 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr17:53,102,534...53,105,400
Ensembl chr17:53,102,534...53,105,400
|
|
G |
Mrpl35 |
mitochondrial ribosomal protein L35 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MRPL35 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:99,738,792...99,749,665
Ensembl chr 4:99,738,792...99,746,560
|
|
G |
Mrps18c |
mitochondrial ribosomal protein S18C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MRPS18C mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:10,440,691...10,446,909
Ensembl chr14:10,440,691...10,446,909
|
|
G |
Mrps21 |
mitochondrial ribosomal protein S21 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MRPS21 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:197,974,758...197,982,385
Ensembl chr 2:197,974,761...197,982,385
|
|
G |
Msh3 |
mutS homolog 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MSH3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:21,790,048...21,931,791
Ensembl chr 2:21,790,044...21,931,720
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MT2A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Mtfr2 |
mitochondrial fission regulator 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MTFR2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:15,834,779...15,850,424
Ensembl chr 1:15,782,477...15,860,624
|
|
G |
Mtif3 |
mitochondrial translational initiation factor 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MTIF3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:9,846,355...9,857,548
Ensembl chr12:9,846,398...9,857,548
|
|
G |
Mturn |
maturin, neural progenitor differentiation regulator homolog |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MTURN mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:84,854,341...84,875,300
Ensembl chr 4:84,854,386...84,871,757
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MVD mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:55,258,910...55,268,933
Ensembl chr19:55,258,905...55,268,951
|
|
G |
Myadm |
myeloid-associated differentiation marker |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MYADM mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:64,438,465...64,448,332
Ensembl chr 1:64,438,472...64,446,818
|
|
G |
Myh9 |
myosin, heavy chain 9 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MYH9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:118,740,005...118,792,507
Ensembl chr 7:118,741,110...118,792,625
|
|
G |
Myl6 |
myosin light chain 6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MYL6 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:2,906,137...2,909,193
Ensembl chr 7:2,906,137...2,909,179
|
|
G |
Myl6b |
myosin light chain 6B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MYL6B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:43,831,778...43,833,044
|
|
G |
Myl9 |
myosin light chain 9 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MYL9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:152,857,573...152,863,961
Ensembl chr 3:152,857,592...152,863,960
|
|
G |
Myo1b |
myosin Ib |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of MYO1B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:54,706,005...54,766,054
Ensembl chr 9:54,558,202...54,766,054
|
|
G |
Mzf1 |
myeloid zinc finger 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of MZF1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:65,520,827...65,533,233
Ensembl chr 1:65,522,118...65,533,212
|
|
G |
Mzt2b |
mitotic spindle organizing protein 2B |
multiple interactions |
|